Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS5338839 A
Publication typeGrant
Application numberUS 07/853,913
Publication dateAug 16, 1994
Filing dateMar 19, 1992
Priority dateApr 12, 1988
Fee statusPaid
Publication number07853913, 853913, US 5338839 A, US 5338839A, US-A-5338839, US5338839 A, US5338839A
InventorsRonald D. G. McKay, Urban Lendahl
Original AssigneeMassachusetts Institute Of Technology
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
DNA encoding nestin protein
US 5338839 A
Abstract
A gene (SEQ ID NO: 1 or SEQ ID NO: 3) encoding a protein, nestin, whose expression distinguishes neural multipotential stem cells and brain tumor cells from the more differentiated neural cell types (e.g., neuronal, glial and muscle cells).
Images(15)
Previous page
Next page
Claims(5)
We claim:
1. Isolated DNA encoding nestin protein and consisting of the nucleotide sequence of SEQ ID NO: 1.
2. Isolated DNA encoding nestin protein and consisting of the nucleotide sequence of SEQ ID NO: 3.
3. Isolated DNA encoding nestin protein consisting of a nucleotide sequence which hybridizes to the DNA sequence of SEQ ID NO: 3 under high stringency conditions.
4. Isolated DNA which encodes a protein of mammalian origin whose expression distinguishes neural multipotential stem cells from neuronal, glial and muscle cells wherein the amino acid sequence of the encoded protein is SEQ ID NO: 2.
5. Isolated DNA which encodes a protein of mammalian origin whose expression distinguishes neural multipotential stem cells from neuronal, glial and muscle cells wherein the amino acid sequence of the encoded protein is SEQ ID NO: 4.
Description
GOVERNMENT FUNDING

Work described herein was supported by funding from the National Institutes of Health.

RELATED APPLICATION

This application claims priority to PCT/US92/01375 filed Feb. 21, 1992 and is a continuation-in-part of U.S. Ser. No. 07/660,412, filed Feb. 22, 1991, now abandoned which is a continuation-in-part of U.S. Ser. No. 07/603,803, filed Oct. 25, 1990, now abandoned which is a continuation-in-part of U.S. Ser. No. 07/201,762, filed Jun. 2, 1988 and now abandoned, which is a continuation-in-part of U.S. Ser. No. 07/180,548, filed Apr. 12, 1988 and now abandoned.

BACKGROUND

Brain tumors are a leading cause of cancer deaths in people under the age of 35. An important concept in our understanding of brain tumors is that the neoplastic cells may arise from undifferentiated neuroectodermal cells (Rubinstein, L. J. J. Neurosurg 62: 795-805 (1985)) .

At the gastrula stage of central nervous system (CNS) development, neuroectoderm, forming the neural plate is derived from ectoderm which has been induced by underlying mesoderm. (Spemann, H. Yale University Press 1938)). The neural plate then folds, in the process called neurulation, to form the neural tube. The cells of the neural tube are the precursors for the major differentiated cell types in the central nervous system: astrocytes, oligodendrocytes, and the various types of neuron (Sauer, F. C. J. Comp. Neurol. 62: 377-405 (1935)). The cells of the neural tube may also be the precursors to neoplastic cells which form brain tumors.

Recent success in "tagging" individual CNS precursors and their daughter cells, either through infection by a marker-bearing retrovirus or by injection of stable, specific dyes and enzymes, has shown that neurons and non-neuronal cells (i.e., glia cells) are often derived from a common precursor. In retina a common precursor for neurons and the Mueller glial cell exists very late in development (Holt, C. E., T. W. Bertsch et al., Neuron 1: 15-26 (1988); Turner, D. L. and C. L. Cepko, Nature 238: 131-136 (1987); Wetts, R. and S. E. Fraser, Science 239: 1142-1145 (1988); a common precursor for different neuronal and glial cell types has also been demonstrated in cortex and tectum (Luskin, M. B., A. L. Pearlman et al., Neuron 1: 635-647 (1988); Price, J. and L. Thurlow, Development 104: 473-482 (1988); Walsh, C. and C. Cepko, Science 241: 1342-1345 (1988)).

Tissue culture systems have provided additional information about the differentiation potential of CNS stem cells. Single-cell microculture of embryonic day 14 rat forebrain has produced clones containing both neurons and glia (Temple, S. Nature 340: 471-473 (1989)). Analysis of a later precursor in the glial differentiation pathway has established specific factors influencing differentiation to oligodendrocytes or type II astrocytes (Raff, M Science 243: 1450-1455 1989)). Cell lines established by immortalization of CNS stem cells also reflect features of the stem cell and can differentiate along both the neuronal and glial pathways (Cepko, C. L. Ann. Rev. Neurosci. 12: 47-65 (1989); Frederiksen, K. et al., supra (1988)).

Antibodies have also proven useful for analyzing stem cells. For example, antibodies A2B5 (Raff, M. C. supra 1989) D1.1 (Levine, J. M., L. Beasley et al., J. Neurosci 4: 820-831 (1984), Rat 401 (Hockfield, S. and R. McKay, J. Neurosci 5: 3310-3328 (1985), and antisera against the intermediate filament vimentin (Bignami, A., T. Raju et al Dev. Biol 91: 286-295 (1982); Federoff, S. Molecular Bases of Neural Development (1985); Tapscott, S. J., G. S. Bennett et al., Dev. Biol. 86: 40-54 (1981) bind to antigens enriched in the proliferative zone of the neural tube. However, A2B5 and D1.1 recognize glycolipid epitopes and are less useful for analysis of gene expression. Vimentin, which appears transiently in brain development, is an ambiguous marker largely because of its promiscuous expression in many cultured cells as well as in a variety of developing and differentiated tissues (Traub, N. Intermediate filaments: a review. Berlin, SpringerVerlag (1985)).

The correlation between Rat 401 and proliferating cells in the developing nervous system has been examined in detail. Rat 401 was found to recognize a transient population of embryonic columnar epithelial cells and radial glial cells in many regions of the CNS (Hockfield, S. and McKay J. Neurosci. 5: 3310-3328 (1985)). The number of Rat 401 positive cells, their proliferative rate, and the developmental kinetics of Rat 401 expression relative to neuronal differentiation revealed that the immediate precursors to neurons are also Rat 401 positive (Frederiksen and McKay, J. J. Neurosci 8: 1144-1151 (1988)). Neither neurons nor glia in the adult brain express the epitope recognized by the Rat 401 antibody.

Although "tagging", tissue culture systems and antibodies have proven useful in analyzing neural precursor cells, there is still an incomplete understanding of the lineage of tumor development. For example, medulloblastoma, a common brain tumor of children, is associated predominantly with the cerebellum and brain stem. Medulloblastoma tumors contain cell types with differentiated characteristics of neurons, glia and muscle (Rubinstein, supra 1985; Coakham H. B., et al., J. Clin. Pathol. 38: 165-173 (1985); Velasco, M. E. et al., Surg. Neurol. 23: 177-182 (1985); Hayashi, K. et al., Acta Pathologica Japonica 37: 85-96 (1987); Cras, P. et al., Acta. Neuropathol 75: 377-384 (1988)).

Because of the presence of multiple differentiated cell types found in these tumors, Bailey and Cushing (Bailey, P. and H. Cushing, Arch. Neurol. Psychiatry 14: 192-224 (1925) proposed that rather than being multiple coincident tumors, they were derived from a multi-potential stem cell, which they called a "medulloblast". According to this model, a medulloblastoma tumor would result from uncontrolled proliferation and differentiation of the medulloblast. However, the hypothetical medulloblast has not been identified.

Due to the incomplete understanding of brain tumor development, there is currently no adequate assay for detecting brain tumors at an early stage in their development. In addition, there is no specific noninvasive method of treating brain tumors. Methods of detecting and treating brain tumors would be very useful.

SUMMARY OF THE INVENTION

The present invention relates to a gene encoding a protein whose expression distinguishes neural multi-potential stem cells and brain tumor cells from the more differentiated neural cell types (e.g. neuronal, glial and muscle cells) of the mammalian brain.

The present invention relates to the nestin gene, particularly a nestin gene of mammalian origin, and the encoded nestin protein. As described herein, two nestin genes of mammalian origin, the rat nestin gene and the human nestin gene, have been isolated and sequenced. The coding sequence of the rat nestin gene transcript is 5415 bp, which corresponds to an expected molecular weight of approximately 200 kD for the nestin protein. The relative molecular weight of the nestin protein as determined by SDS polyacrylamide gels is approximately 240 kD. The predicted amino acid sequence of the rat nestin gene product shows that nestin defines a distinct sixth class of intermediate filament protein.

The present invention also relates to the human nestin gene and the encoded human nestin protein. The coding sequence of the human nestin gene transcript is 4854 bp. The predicted amino acid sequence is 1618 amino acids in length, and shows significant sequence homology with the rat nestin sequence.

The present invention further relates to methods of detecting the expression of nestin as a means of diagnosing a predisposition to the development of a brain tumor or the presence of a brain tumor in an adult individual. In one embodiment, DNA present in a sample from the brain of an adult individual is hybridized to a DNA probe which is complementary to all or a portion of the nestin gene. As used herein, the term the nestin gene includes the human nestin gene whose sequence is represented herein, the rat nestin gene whose sequence is also represented herein and equivalent genes from other species, such as those which are substantially homologous to the human or the rat gene sequence. Detection of hybridization is an indication of a predisposition to the development of a brain tumor or the presence of a brain tumor. In another embodiment, cerebral spinal fluid or a serum sample from the brain of an adult individual can be stained with anti-nestin antibodies. Detection of stained cells is an indication of a predisposition to the development of a brain tumor or the presence of a brain tumor.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A-1H is the nucleotide sequence of rat nestin (SEQ ID NO: 1).

FIG. 2 is the deduced amino acid sequence of rat nestin (SEQ ID NO: 2).

FIG. 3A-3D is the nucleotide sequence of human nestin (SEQ ID NO: 3).

FIG. 4A-4B is the deduced amino acid sequence of human nestin (SEQ ID NO: 4).

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a gene of mammalian origin encoding a protein whose expression distinguishes neural multipotential stem cells and brain tumor cells from the more differentiated neural cell types (e.g., neuronal, glial and muscle cells of the adult brain).

The present invention more particularly relates to the nestin gene and the encoded proteins and their use in diagnosing tumors of the brain, such as medulloblastomas, gliablastomas and oligodendroglioma. As described herein, the human nestin gene and the rat nestin gene have been isolated and sequenced. In addition, expression of the nestin gene and its structural features are described. The intracellular distribution of the nestin gene product, both in an embryonic rat brain cell line (ST15A) and human brain tissue, including tumor cells, using immunocytochemical and immunohistochemical techniques is also described. Finally, nestin expression in the developing human central nervous system and brain tumor samples is also described herein.

CLONING AND CHARACTERIZATION OF THE RAT AND HUMAN NESTIN GENE The Rat Nestin Gene

A cDNA library in the expression vector lambda gt11 was constructed from poly(A)+ RNA from CNS of embryonic day 15 (E15) rat embryos as described in detail in Example 1. The library was screened with the monoclonal antibody Rat 401 after induction of protein expression and immunopositive plaques were identified. The cDNA insert from the most immunopositive clone, gt11.401.19, was used as probe to isolate additional clones, gt10,401:16, gt10,401:18 and gt10.401:9, in a lambda gt10 library from rat E15 CNS constructed in parallel with the gt11 library. A number of hybridizing clones were identified and sequenced and together represent 5333 base pair (bp) of transcribed sequence, including 404 bp of 3' untranslated sequence and a consensus polyA addition site.

The remaining portion of the nestin gene was obtained from genomic sequences. Genomic Southern blots, even when hybridized at low stringency, revealed a pattern consistent with a single rat gene. A genomic rat library in the vector Charon 4A was screened with the nestin cDNA clones. Hybridizing clones were organized by restriction mapping and the region upstream of the cDNA clone gt10.401:9 was sequenced.

An open reading frame continues for an additional 600 bp from the 5' end of the most upstream cDNA clone. This region from the genomic clone Cha.401:14 was subdivided into three different fragments with the restriction enzyme BamH1. These three fragments all hybridized to an mRNA of the correct size, 6.2 kb, when used as probes on Northern blots with rat E15 CNS RNA.

The exact location of the 5' end was determined by a combination of S1 nuclease mapping and primer extension. A probe (bp -121 to +194 relative to +1= the subsequently defined transcription start) was generated overlapping the end of the genomic open reading frame by polymerase chain reaction between two specific primers. This PCR product protected a 194 bp fragment in S1 nuclease analysis. Primer extension from the downstream primer used to generate the PCR fragment also produced a 194 bp fragment. The fact that these two experiments gave the same fragment suggests that the transcription start site has been defined.

FIG. 1A-1H shows the nucleotide sequence of the rat nestin gene (SEQ ID NO: 1). The total length of the rat nestin gene is 11,236 base pairs (bp). The total length of the nestin gene transcript is 5945 bp, excluding the poly A tail. There are two potential initiation codons at positions +127 and +160. Assuming the first methionine is the initiation codon, the coding sequence is 5415 bp. FIG. 2 shows the deduced amino acid sequence (SEQ ID NO: 2) encoded by the rat nestin gene, which is 1805 amino acid residues in length. This corresponds to a protein of an expected molecular weight of approximately 200 kD; the relative molecular weight as determined by migration on SDS polyacrylamide gels is approximately 240 kD (Hockfield and McKay, supra (1985)). Sequence comparison of cDNA and genomic clones reveals three introns at positions 912, 1038, and 1111 in the transcribed region.

To confirm that the cloned gene indeed represents the gene encoding the Rat401 antigen, a synthetic peptide from the C-terminal 20 amino acids was made. The extreme C-terminus was chosen because it is not included in the clone recognized by the original monoclonal antibody, and therefore represents a distinct epitope. A polyclonal antiserum against the peptide was raised in rabbits and identifies a band in Western blots and a pattern in immunostaining experiments which are indistinguishable from that recognized by the monoclonal antibody Rat 401.

Structural Features of the Rat Nestin Gene

The sequence of the entire transcribed region of the rat nestin gene was compared to the Genbank and EMBL databases. The only significant similarities found are to the five classes of intermediate filaments: acidic keratins (class I); basic keratins (class II); desmin, glial fibrillary acidic protein, peripherin, and vimentin (class III); the neurofilament triplet (class IV); and nuclear lamins (class V) (Steinert and Roop, 1988)).

The similarity between the nestin gene and the genes of the other five classes of intermediate filaments ranges from 16 to 29% at the amino acid level in a 307 amino acid long region starting close to the N-terminus of the nestin gene, corresponding to the conserved alpha-helical rod or "core" domain of the intermediate filaments. This region of the predicted nestin amino acid sequence also contains a repeated hydrophobic heptad motif characteristic of intermediate filaments. The degree of amino acid similarity is comparable to that found between different classes of intermediate filament, both in degree and in location, i.e., conserved heptad-containing alpha-helical stretches within the core domain are separated by less well conserved, non-heptad spacers (Steineft, P. M. and D. R. Roop, Ann. Rev. Biochem. 57: 593-625 (1988)). The locations of the nestin gene's three introns are not conserved with respect to those of other classes of intermediate filaments.

In the regions outside the conserved rod domain, no strong similarities to other characterized genes were found. The N-terminal domain is only 11 amino acid residues long, shorter than in other intermediate filaments. The large C-terminal domain loosely resembles those of neurofilaments in that it is highly charged, bears glutamate-rich regions, and features a repeat, in this case the 11 amino acid motif S/P-L-E-E/K-E-X-Q-E-S/L-L-R (underlined residues are strongly conserved). There are approximately 35 of these repeats in the region between amino acids 512 and 1050.

The deduced amino acid sequence (SEQ ID NO: 2) of nestin suggests that it is a member of the intermediate filament protein family. However, its degree of sequence homology to other intermediate filaments in the core domain, its dissimilarity in the head and tail domains, and its different splicing pattern suggest that it defines a new class of intermediate filament protein.

The Human Nestin Gene

As described in detail in Example 5, the human nestin gene was isolated using low stringency DNA hybridization of a human genomic bacteriophage lambda library with a rat nestin probe.

FIG. 3A-3D shows the nucleotide sequence of the human nestin gene (SEQ ID NO: 3). The total length of the human nestin gene sequence is 4854 bp. FIG. 4A-4B shows the deduced amino acid sequence (SEQ ID NO: 4) encoded by the human nestin gene which is 1618 amino acid residues in length. The alignment of the deduced amino acid sequences of human nestin with the deduced amino acid sequence of rat nestin showed greater than 75% sequence similarity between the two sequences, with greater than 60% sequence identity.

DEVELOPMENTAL EXPRESSION OF THE RAT AND HUMAN NESTIN GENE AND ENCODED PRODUCT Developmental Expression of the Rat Nestin Gene

During development, CNS stem cells differentiate into neurons and glia on a stereotyped schedule; different brain regions become post-mitotic at different times. The nestin protein was originally identified by the Rat 401 antibody, which transiently stains radial glial cells of the neural tube in cross sections of rat embryos (Fredericksen, K. and R. McKay, J. Neurosci 5: 3310-3328 (1988); Hockfield and McKay, supra (1985)). The distribution of staining in the neural tube at different developmental stages, combined with quantitative double-label experiments using tritiated thymidine autoradiography and FACS cell cycle analysis, showed that expression of the Rat 401 antigen was localized to proliferating CNS stem cells during embryogenesis (Frederiksen and McKay, supra (1988)) and U.S. patent application Ser. Nos. 180,548, abandoned; 201,762, abandoned and 603,803, abandoned herein incorporated by reference. These experiments have been extended by analyzing the developmental expression of the nestin gene.

Northern blots of RNA from E15 rat CNS or from the Rat 401 positive cell line ST15A were probed with nestin cDNA inserts, a single 6.2 kb mRNA species was identified. To investigate the temporal profile of nestin RNA expression in the developing CNS, representatives of early (cerebrum) and late (cerebellum) developing regions of the brain were compared.

In cerebrum, nestin expression was found to decline from a maximum on day El6, such that only extremely low levels of RNA could be detected at day P9 and P12 and none at all in the adult cerebral cortex, even after long exposures. The loss of nestin mRNA precisely parallels the decline of Rat 401 positive stem cells in cerebrum during neurogenesis (Frederiksen and McKay, supra (1988)). The postnatal cerebellum expresses the nestin gene with a maximum on day P5; no expression can be detected after day P9. Again, this pattern closely matches the numbers of Rat 401 positive cells in developing cerebellum.

Nestin is not detected by Northern blot analysis in adult tissue. The loss of nestin expression coincides with terminal differentiation of these early multi-potential cells. There are two important implications of these results. First, nestin appears to be a general marker for the CNS stem cell from the newly closed E11 neural tube through the postnatally developing cerebellum. Second, nestin expression is a consequence of transcriptional regulation of the gene.

The only expression of nestin observed outside developing CNS is traces of nestin message from day P4 developing skeletal muscle. This finding is consistent with previous observations from cross sections of rat embryos, where Rat 401 staining in the developing somites was observed (Hockfield and McKay, supra (1985)). Developing nervous tissue and developing skeletal muscle may share unexpected kinship with regard to their potential fates.

Intracellular Distribution of the Nestin Gene Product in the ST15A Cell Line

The associations of nestin with different components of the cytoskeleton were analyzed by a series of double-label immunocytochemistry experiments. These experiments were carried out in the immortalized CNS precursor cell line ST15A which expresses, in addition to components of microtubules and microfilaments, nestin and the intermediate filament vimentin. ST15A produces a nestin mRNA indistinguishable by Northern blot analysis from that found in E15 CNS.

In the first set of double-label experiments the intracellular distribution of the nestin gene product, detected by the monoclonal Rat.401 antibody and an appropriate second antibody, was compared to the distribution of actin, tubulin and vimentin. The latter two proteins were detected by polyclonal antibodies with matching second antibodies while the actin pattern in microfilaments was visualized by rhodamine-conjugated phalloidin.

The intracellular distributions of nestin, microtubules (tubulin), and microfilaments (actin) are quite different. Microtubules are more evenly distributed in the cell with no particular aggregation around the nucleus, whereas nestin is found in a fiber-like pattern, with a pronounced perinuclear accumulation. We also observe distinct differences when microfilaments and nestin are stained in the same cell: microfilaments form straight and parallel fibers, in contrast to the gently curved fibers of nestin.

Differences in nestin and vimentin staining in the same ST15A cells are much less clear. Vimentin staining is stronger than nestin in the cell periphery, and there are regions where intensity varies between the two proteins, but common features are also evident. The overall organization of the two networks is quite similar, with filament arrays radiating out from a perinuclear center. Moreover, there are regions in cells where it seems likely that nestin and vimentin colocalize.

In another set of experiments, microfilaments and microtubules were disrupted by cytochalasin B and colchicine, respectively, and the effects on nestin distribution analyzed. When ST15A cells were treated with 10 ug/ml cytochalasin B for one hour the microfilaments became highly disorganized, while the overall morphology of the nestin network was preserved. Microtubules also remained intact after the cytochalasin B treatment. Colchicine treatment (25 ug/ml) for 24 hours caused a collapse of the microtubules. The nestin network could still be identified, although the perinuclear distribution became much more prominent. A similar pattern was observed for vimentin as has been previously reported (Hynes, R. O. and A. T. Destree, Cell 13:151-163 (1978): Monteiro, M. J. and D. W. Cleveland, J. Cell Biol. 108: 579-593 (1989). Microfilaments were essentially unaffected by the colchicine treatment. The inferred relationship of nestin to intermediate filaments based on its deduced amino acid sequence is thus supported by the intracellular distribution of the nestin gene product under various conditions.

ST15A Cells have Features Expected of a Neural Precursor to Brain Tumors

"The prevailing name `medulloblastoma` given by Bailey and Cushing (1925), is unfortunate because there is no embryonal cell that has been identified as a medulloblast." This sentence begins the discussion of medulloblastoma in a prominent text on neural tumors (Russell, D. and L. J. Rubinstein, Pathology of Tumors of the Nervous System, Baltimore, Williams and Wilkins (1989)). The following presents evidence that a cell line derived from rat cerebellum, ST15A, has features expected of a medulloblast.

ST15A was derived from postnatal day 4 rat cerebellum. In the rat, as in other mammals, much of cerebellar development occurs after birth, so that there are a large number of dividing precursor cells present at the time from which this line was derived. Thus, ST15A is derived from the appropriate tissue and stage of development. It has previously been shown that ST15A cells can differentiate along neuronal and glial pathways. The following experiments, which are described in detail in Example 3, show that ST15A cells can also differentiate into muscle. This result suggests that a single neuroectodermal cell can give rise to the different cell types found in brain tumors.

The cerebellar cell line ST15A was one of several cell lines obtained by infecting primary rat cerebellar cells with a recombinant retrovirus carrying SV40 T-antigen. A temperature sensitive allele of T-antigen was used to establish these cell lines. At the permissive temperature (i.e., when the T-antigen protein is active) the cells proliferate and express the intermediate filament protein nestin.

At the non-permissive temperature the T-antigen protein is rapidly degraded and the cells differentiate into either neurons or glial cells depending on the conditions. The differentiation into neurons and glial cells is best accomplished by growing ST15A cells in co-culture with primary cerebellar cells. Partial differentiation has also been observed when ST15A cells are cultured alone; serum-free medium promotes neuronal differentiation and medium containing fetal calf serum promotes glial differentiation.

ST15A cells also can differentiate into muscle cells. This fate was first noted when spontaneously contracting cells were observed in long term cultures of ST15A at 39 C., the non-permissive temperature for T-antigen. Horse serum is often used to support the differentiation of primary myoblasts. When ST15A cells are grown in horse serum at 39 C., they reproducibly differentiate into multi-nucleate cells which express muscle specific proteins, regenerative action potentials and spontaneously contract.

ST15A cells grown for two days at 33 C. in 10% fetal calf serum (FCS) in DMEM grew in a disorganized manner; in contrast ST15A cells grown at 33 C. in 10% horse serum at 39 C. became aligned. The monoclonal antibody Rat 401 recognizes the 220 kD intermediate filament protein nestin. ST15A cells express nestin at both 33 C. and 39 C. A second monoclonal antibody which recognizes a skeletal and cardiac muscle isotype of troponin T was reacted with the cells (Lin, J. Biol. Chem. 263: 7309 (1988)). Immunofluorescence shows that troponin T expression is induced when ST15A cells are cultured at 39 C. in horse serum.

Immunoblots of proteins extracted from ST15A cells verify that anti-troponin T antibody recognizes a strong band of 38 Kd, the appropriate molecular weight, in the cells grown at 39 C. in horse serum; at 33 C. no band is present. The troponin band in ST15A co-migrates with troponin extracted from rat postnatal day 4 muscle. The double band seen in both muscle cells and differentiated ST15A cells may represent the adult and embryonic isoforms of troponin T which differ by 3,000 daltons (Lin, J. Biol. Chem. 263: 7309 (1988)). These two isoforms are derived from the same primary transcript by differential splicing. Lanes carrying the same amount of protein were also probed for nestin with the monoclonal antibody Rat 401. Nestin is present at both temperatures but at elevated levels at the higher temperature. The lower bands are proteolytic fragments of nestin which are often present in protein extracts even in the presence of protease inhibitors. Nestin is also present in postnatal rat muscle.

A family of DNA binding factors has been shown to play a critical role in the differentiation of muscle. These proteins, myoD1, myogenin, myf5 and herculin/MRF4, contain DNA binding motifs of the helix-loop-helix type in a region of homology to c-myc (Wright, W. E., et al., Cell. 56: 607 (1989); Miner, J. H. and B. Wold, Proc. Nat. Acad. Sci. 87: 1089-1093 (1990); Davis, R. L. et al., Cell. 51: 987-1000 (1987); Braun, T et al., EMBO J 8: 701-709 (1989); Rhodes S. J. and S. F. Konieczny, genes and dev. 3: 2050-2061 (1989). The expression of these factors at the mRNA level in ST15A cells as they differentiate into muscle was examined.

Northern blot analysis of total RNA from differentiating ST15A cells probed with the indicated sequences was performed. Each probe hybridized only to the bands of the expected mobilities. MyoD1 is expressed in passaging ST15A cells at the permissive temperature for the T antigen and continues to be expressed when the cells are shifted to 39 C. Myogenin is not expressed under normal growth conditions but is expressed by 2 days after confluent cells are shifted to 39 C. in horse serum (HS); if confluent cells are placed in HS and held at 33 C., the induction of myogenin expression is dramatically inhibited.

Herculin/MRF4 was found in adult skeletal muscle but was not detected in ST15A. Myf5 gave a very weak signal in ST15A cells compared to the myoblast cell line C2C12. Nestin mRNA accumulates with time at 39 C., as does the protein. b-actin serves as a control for the amount of RNA at 33 C. and in the short time points at 39 C.; the decrease in b-actin signal at 3 and 7 days at 39 C. may be due to the changing composition of the cytoskeleton accompanying differentiation, as levels of myoD1 mRNA appear constant throughout the experiment. These results indicate the ST15A cells express myogenic transcription factors and that the induction of myogenin correlates with the differentiation into the muscle fate.

As expected of muscle cells, ST15A cells become multinucleate as they differentiate. The most striking similarity to muscle, which initiated this series of experiments, was that ST15A cells grown to confluence in FCS at 33 C. and cultured for up to 15 days at 39 in 10% horse serum can contract spontaneously. The initial action potentials were generated by a series of hyper-polarizing pulses. The final hyper-polarizing pulse was followed by a train of spontaneous action potentials. Spontaneous action potentials were seen after 12 days at 39 C. in 10% horse serum.

Coincident with the appearance of contracting cells, the resting membrane potential falls and it becomes easier to stimulate trains of action potentials with hyperpolarizing current pulses. ST15A cells also twitched in response to stimuli which elicited action potentials. These results show that ST15A cells differentiate into muscle, expressing myogenic transcription factors, muscle-specific cytoskeletal components and electrical excitability.

An interesting question raised by the properties of ST15A cells is whether primary cerebellar cells can differentiate into the muscle fate. Dissociated cells from postnatal day 5 rat cerebellum were cultured for 6 days under conditions which promote muscle differentiation of ST15A cells (39 C. in the presence of 10% horse serum) and stained with monoclonal antibody against troponin T. These culture conditions promote extensive differentiation of neurons and glia. Troponin T positive cells with an elongated, multinucleate morphology of muscle cells were also seen, but these cells were very rare, occurring less than one per hundred thousand cells.

Developmental expresssion of Human Nestin Gene

To characterize human nestin and determine the timing of its induction in the normal human developing CNS, studies were carried out, to examine this class VI IF protein in the normal human developing central nervous system (CNS), human brain tumor derived cell lines, and tissue samples of human CNS tumors.

Human nestin exhibited biochemical and immunochemical properties similar to those of rat nestin. Further, in the human, nestin was detected immunohistochemically in several different types of immature human CNS cells, i.e. germinal matrix cells, neuroepithelial cells lining the central canal, radial glia and endothelial cells. Nestin appeared in these cells at the earliest gestational age (i.e., 6 weeks) examined here and then it declined in all but the endothelial cells at later embryonic stages. Nestin also was detected by immunocytochemistry in 6 of 7 primitive neuroectodermal tumor cell lines and in both of the malignant glioma cell lines examined. In these cell lines, nestin co-localized incompletely with bundles of IFs containing other IF proteins (i.e. vimentin, glial filament, nuerofilament). Nestin was ubiquitous in a wide variety of brain tumors, but was most prominent in gliomas. These studies document the existence of a human counterpart of rat nestin.

Distribution of the Nestin Gene Product in the Human Developing CNS

Cervical levels of six developing human spinal cords with gestational ages (GAs) of 6 to 40 weeks were immunohistochemically stained with anti-nestin 129. The spinal cord of the 6 weeks GA human fetus was composed of three distinct layers, i.e. a layer of primitive neuroepithelial cells lining the central canal, a mantle layer and an outer marginal layer. Anti-nestin 129 stained most cells in the primitive neuroepithelial layer, i.e. the presumptive miltipotential stem cells that give rise to CNS neurons and glia. In addition, thin elongated radial glial fibers extending from the primitive neuroepithelial layer to the subpial region were stained by this antiserum. These neuroepithelial stem cells and radial glial fibers also expressed vimentin but not GFAP. Neuroblasts in the mantle layer (identified by their morphology and NF protein positively) did not express nestin.

At 11 weeks GA, cells in the ependymal layer were positively stained with anti-nestin 129, as were radial glial fibers. These radial glial fibers were also stained with the anti-vimentin MAb. Nestin immunoreactivity decreased at 17 weeks GA and disappeared at 20 weeks GA. From this gestational age to maturity, GFAP positive glial cells and NF positive neurons were seen in the spinal cord, but no elements other than endothelial cells were nestin positive.

The telencephalic germinal matrix of two cases with GAs of 17 and 20 weeks were examined with anti-nestin 129. At both time points, many presumptive neuroepithelial stem cells in the germinmal matirx cells were nestin positive. These neuroepithelial precursor cells also were labeled by the anti-vimentin MAb, but no germinal matrix cells were stained by the MAbs to GFAP or NF proteins. At 40 weeks GA, a well defined germinal matrix was not evident, but clusters of morphologically immature cells (presumably residual, multipotential precursor cells) were seen in the subependymal region. Nestin immunoreactivity was recognized in only a few of these cells.

To determine if neuroepithelial precursors in the cerebellum also expressed nestin, four developing human cerebelli at GAs of 17 to 40 weeks were studied. Late in development, the cerebellar cortex has four distinct layers, i.e. the internal and external granular layers, the Purkinje cell layer and the molecular layer. However, these layers were not yet evident at 17 weeks GA and Purkinje cells were not recognizable by morphological criteria. Nevertheless, immature NF positive cells were observed at 17 weeks GA in the superficial internal granular layer, and these cells probably correspond to nascent Purkinje cells. Nestin immunoreactivity was detected at this time in radial glial cells in the internal granular layer and in radial glial processes that extended to the external granular layer. These radial glial cells, which mature into the Bergmann glia of the adult cerebellum, also were stained by the antivimentin MAb (data not shown), but not by the anti-GFAP MAb. However, the anti-GFAP MAb did stain ependymal cells lining the fourth ventricle. At 20 weeks GA, nestin immunoreactivity in radial glia was markedly diminished and by 40 weeks GA, it was weakly present in only a few radial glia fibers, while the blood vessel endothelial cells at 40 weeks GA were clearly nestin positive. In contrast, radial glial fibers expressed both GFAP and vimentin (data not shown) at these time points.

Nestin Expression in Brain Tumor-derived Cell Lines

Indirect immunofluorescence studies of 9 well characterized human brain tumor derived cell lines showed variable nestin immunoreactivity in 6 of 7 primitive neuroectodermal tumor (PNET) cell lines, and very intense nestin staining in 2 glioma cell lines. Table 1 summarizes the data on the expression of nestin and other IF proteins in these cell lines.

                                  TABLE 1__________________________________________________________________________IMMUNOFLUORESCENCE ASSAY OF BRAINTUMOR-DERIVED CELL LINESCELL LINES    NESTIN          VIMENTIN                  GFAP                      NF-L                          NF-M                              NF-H__________________________________________________________________________Daoy     -     +       -   -   -   -D283 Med +     +       -   +   +   +D341 Med +     +       -   -   +   +D384 Med +     +       -   +   +   +D425 Med +     +       -   +   +   +D458 Med +     +       -   +   +   +CHOP707m +     +       -   +   -   -U251 MG  +     +       +   -   -   -__________________________________________________________________________ Summary of the data obtained from the indirect immunofluorescence studies of each cell line. The patterns of staining are described as - = no staining, + = positive staining. NF-L, NFM and NFH are the low, middle and high molecular weight neurofilament subunits, respectively. The following antibodies were used to obtain these data; nestin (rabbit antinestin antiserum 129), vimentin (V9), GFAP (2.2B10), NF-L (NR4, RMS12), NF-M (RMdO20, RMO254, HO14), NF-H (DP1, TA51, RMO24).

Except for CHOP707m, which was derived from a cerebral neuroblastoma (Baker, D. L. et al., Am. Neurol. 28:136 (1990)), the other 6 PNET cell lines were obtained from cerebellar medulloblastomas (see Hockfield, S. et al., J. Neurosci 5:3310 (1985)) and citations therein). Daoy does not exhibit any evidence of glial or neuronal differentiation and it was nestin negative, while the other 6 PNET cell lines resembled that of embryonic neuroblasts (He, X. et al., J. Neuropathol. Exp. Neurol. 48:48 (1989)). Double immunofluorescent staining of D283 Med, which is the most differentiated PNET cell line, showed incomplete co-localization of nestin and NF proteins in bundles of IFs in the same cells. Similar observations were made using nestin and vimentin antibodies. CHOP707m expressed extensive nestin immunoreactivity and double immunofluorescence of nestin and vimentin in this cell line co-localized both proteins in the same cells, but the nestin positive filament bundles were located mainly in the perinuclear area while vimentin positive filament bundles were present throughout these cells. The Daoy line expresses vimentin, but not NF proteins, GFAP or other molecular markers of neurons or glia (He, X. et al., J. Neuropathol. Exp. Neurol. 48:48 (1989)). Hence, Daoy is the least differentiated PNET cell line, and it did not express nestin. The foregoing co-localization studies also indicated that the anti-nestin 129 did not cross react with vimentin or NF proteins.

Since nestin is expressed primarily in CNS stem cells and is eliminated during the progressive maturation of the progeny of these stem cells, the Daoy cell line may resemble a CNS precursor that subsequently develops into a vimentin and nestin positive CNS stem cell like those observed here in the human spinal cord at a GA of 6 weeks. Alternatively, tumor cell lines contain genetic mutations and their phenotype may not fully replicate that of normal cells. However, the 2 glioma cell lines (U251 MG and U373 MG) resembled immature spinal cord radial glia (i.e. at 11 weeks GA) since these cells co-expressed nestin, GFAP and vimentin in the triple fluorescence studies.

Finally, Western blot studies were performed which showed that anti-nestin 129 labeled a single band in cytoskeletal extracts of U251 MG cells, and this immunoband had a Mr similar to that of the bacterial TrpE-nestin fusion protein and lower than that of rat nestin expressed in P6 rat cerebellum. The significance of the difference in the Mr of rat and human nestin is unclear and will require further studies. Since these extracts contained vimentin, GFAP and other cytoskeletal proteins, these data further demonstrate the specificity of the anti-nestin antiserum for human nestin.

THE EXPRESSION OF NESTIN IN BRAIN TUMOR TISSUE Brain Tumors Contain Nestin Positive Cells

ST15A cells express properties expected of the precursor to brain tumor cells as described in Example 3. Therefore, brain tumor cells were tested to determine whether they express features in common with ST15A, such as expression of nestin. As described in detail in Example 6, tissue from five medulloblastomas was obtained. Three of these samples came from recurrent tumors occurring in a 16 year old male, a 26 year old male and a 5 year old female. The remaining tumors were newly diagnosed in an 11 year old male and a 10 year old female. The primary tumor in the 11 year old male was also used as a source of cultured cells.

Immunohistochemistry on sections of tissue from each of the five tumors studied showed regions with large numbers of nestin immunoreactive cells. The expression of nestin in medulloblastoma tissue was not uniform and in some cases parts of the tumor tissue showed a few nestin-positive cells among nestin-negative cells. The pre-immune serum showed no reaction with either human embryonic or tumor tissue. The nestin positive cells were small with a cytoplasmic distribution of the antigen. In one tumor, there were groups of aligned nestin positive cells which were very similar in their morphology to the embryonic neuroepithelium.

A cell line which was generated by growing cells out of the medulloblastoma from the 11 year old male was also tested for expression of nestin. Immunocytochemistry with polyclonal anti-nestin antiserum shows that these cells are uniformly positive for nestin expression and reveals the filamentous pattern characteristic of this intermediate filament protein. Western blotting using anti-nestin serum shows that the antigen detected in these cells comigrates with rat nestin.

Sections of normal fetal and adult human cerebellum were also stained with polyclonal antiserum against nestin. The fetal tissue showed many positive cells in the proliferative, external granular layer of the developing cerebellum and in the outer part of the internal granular layer. In contrast, there was no immunoreactivity in cerebellum from a 2.5 year old. These results are consistent with the stem cell specific expression of nestin seen in developing mouse and rat brain.

Utility

The adult cell types of the brain express distinct intermediate filament proteins: neurofilaments are expressed by neurons, peripherin by a subset of neurons (Leonard, Gorham, et al., (1988)), and glial fibrillary acidic protein by astrocytes. The expression of nestin defines an earlier stage in the pathway of intermediate filament gene expression. Early embryonic cells are nestin negative but express certain cytokeratins (Jackson, B. W., C. Grund et al., Differentiation 20: 203-216 (1980)). During neurulation neurectodermal cells become nestin positive. Upon terminal differentiation, CNS cells stop producing nestin and express class III or IV intermediate filaments typical of their differentiated cell type.

Nestin positive neurectodermal cells have been shown to be capable of differentiating into neuronal, glial and muscle cells (i.e., the different cell types found in tumors). Nestin expression has also been directly detected in tumor tissue and in a medulloblastoma derived cell line. Nestin positive cells derived from tumors are likely to be renewing stem cells which give rise to the differentiated cells in the tumor.

The detection of nestin expression in brain cells obtained from an adult using known methods is indicative of the presence of a brain tumor or of neural precursor cells capable of developing into a brain tumor. For the purposes of the subject invention, an "adult" is an individual whose central nervous system is developed and, therefore, contains differentiated cells. For example, the central nervous system of human neonates is in continual development up until the age of about one year. Therefore, a human adult, for the purposes of the subject invention, is an individual who is older than about one year.

Nestin mRNA expression in a brain tissue sample can be detected using a DNA probe; this is indicative of expression of nestin, which is, in turn an indication of a predisposition to the development of a brain tumor or of the presence of a brain tumor in the individual. For example, a sample of brain tissue from of an individual can be hybridized to a DNA probe which is complementary to all or a portion of the nestin gene. Detection of hybridization is an indication of a predisposition to the development of a brain tumor or the presence of a brain tumor.

Alternatively, expression of the nestin protein can be detected using polyclonal antibodies, (e.g., anti-nestin antiserum 129) or monoclonal antibodies (e.g., Rat 401). For example, cerebral spinal fluid or a serum sample from the brain of an individual can be stained with anti-nestin antibodies. Detection of stained cells is an indication of a predisposition to the development of a brain tumor or the presence of a brain tumor.

The finding that neural precursors to tumors express nestin also has important therapeutic implications. For example, the nestin marker enables further investigation into the proliferation and differentiation of the stem cells of a brain tumor, so that existing chemotherapies can be implemented at an earlier stage in the tumor development and so that new methods of inhibiting tumor development can be developed.

The present invention will now be illustrated by the following examples, which are not to be seen as limiting in any way.

EXAMPLE 1 Cloning and Characterization of the Rat Nestin Gene Construction and Screening of Libraries

λgt10 and λgt11 cDNA libraries were constructed from oligo-dT-primed poly(A)+RNA from embryonic day 15 dissected rat CNS according to procedures which were slightly modified from those described (Young, R. A. and R. W. Davis, Proc. Natl. Acad. Sci. USA. 80: 1194-1198 (1983)). The second strand cDNA was synthesized using the RNase H modification of the Okayama-Berg method (Gubler, U. and R. Hoffman, Gene 25: 263-269 (1983)). After induced protein expression, the λgt11 library was screened with the monoclonal antibody Rat 401 (undiluted hybridoma supernatant) and positive clones were visualized with an anti-mouse second antibody conjugated to alkaline phosphatase (Promega Protoblot). Immunopositive clones were selected and the cDNA insert from the clone giving the strongest hybridization signal, λgt11.401:16, was 32 P-labelled (Feinberg, A. P. and B. Vogelstein, Anal. Biochem. 137: 266-267 (1983) and used as probe to screen the λ gt10 library (Benton W. D. and R. W. Davis, Science. 196: 180-182 (1977); Thomas, P. S. Proc. Natl. Acad. Sci. USA. 77: 5201-5205 (1980)). Several clones were identified. A commercial rat genomic DNA library (Clontech) in the vector Charon 4A was screened with 32 P-labelled nestin cDNA inserts as above. A number of hybridizing clones were obtained, and a genomic map comprising 20 kb of the nestin gene region was established by restriction mapping of the genomic clones, cross-hybridizations, and sequencing of selected genomic subclones.

DNA Sequencing and Computer Analysis

cDNA inserts and genomic subclones were sequenced after subcloning into M13mp18, M13mp19, or Bluescript KS+ (Stratagene). M13 phage particles and Bluescript were grown and circular DNA prepared according to standard procedures. Both single stranded (M13) and double stranded (Bluescript) sequencing was performed using a modified T7 DNA polymerase (Sequenase, USB), as suggested by the manufacturer. Approximately 90% of the gene, including all exons and cDNA inserts, was sequenced on both strands. Ambiguous regions were further resolved using deoxyinosine in the standard Sequenase protocol. Computer analysis was performed using the University of Wisconsin Genetics Computer Group program package, including the FASTP and TFASTA algorithms (Devereux, Haeberli et al., 1984)). The complete sequence, including introns, will be stored in the EMBL Database.

Isolation of RNA and Northern Blotting

Tissue was rapidly dissected and quickly frozen in liquid nitrogen. After homogenization in a quanidinium thiocyanate containing buffer, total RNA was isolated by centrifugation through a CsCl cushion (Chirgwin, Przybyla et al., 1979)). Poly(A)+RNA was isolated by an oligo-dT chromatography column (Aviv and Leder, 1972) or by a poly(A)+RNA extraction kit (Fast Trak, Invitrogen). For Northern blot analysis RNA was denatured and electrophoresed in 1% agarose gels containing 2.2 M formaldehyde in 1X MOPS buffer (Maniatis, Fritsch et al., 1982) at +4 C. for 8 hours. The RNA was then transferred to nitrocellulose filters (GeneScreen Plus, New England Nuclear) (Thomas, 1980)). The filters were prehybridized and hybridized (50% formamide, 0.75 M NaCl, 100 mM Tris pH 7.8, 5 mM EDTA, 1% sodium dodecyl sulphate at 42 C. for 16 hours) with 2106 cpm/ml of the 32 P-labeled nestin cDNA insert from λ gt10.401:16 (specific activity 3108 cpm/ug). After hybridization, the filters were washed (final wash=230 minutes at 65 C. in 30 mM NaCl, 4 mM Tris pH 7.8, 0.2 mM EDTA and 0.25% SDS) and exposed to x-ray film with intensifying screens. Quantity and integrity of the RNA were monitored by rehybridizing the blots with a cDNA probe from the human beta-tublin gene under identical conditions. The size of the hybridizing RNA was determined by running RNA molecules of known size (HMW RNA ladder, BRL) in parallel.

S1 Nuclease Mapping and Primer Extension

To generate a probe for S1 nuclease protection experiments, we amplified a region of a genomic clone between two synthetic primers using the polymerase chain reaction (kit from Perkin-Elmer Cetus). The resulting fragment was 315 bp long and located between bp -121 and +194 (bp +1 indicates the subsequently defined initiation of transcription). After 32 P end-labelling, 300 fmole of the fragment was hybridized to 50 ug of E15 CNS rat total RNA or 50 ug of yeast total RNA according to standard procedures, and the S1 resistant hybrids separated on denaturing polyacrylamide gels (Maniatis, T., E. F. Fritsch et al., Molecular cloning: A laboratory manual (Cold Spring Harbor, N.Y.: (1982)). 32P end-labeled restriction digested plasmids and sequencing reactions of known DNAs were used as size standards. The dried gels were exposed to x-ray film. Primer extensions were performed by hybridizing 125 fmole of one of the oligonucleotides used in the polymerase chain reaction (pos +170-+194) to 10 ug of poly(A)+RNA from rat E15 CNS according to standard procedures. The reaction product was subjected to gel electrophoresis as in the S1 nuclease experiments.

Immunocytochemistry

For all experiments cells from the immortalized cell line ST15A were grown for 2 days (to 40% confluence) in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum on sterile, polyornithine coated glass cover slips, as described in U.S. patent applications Ser. Nos 07/603,803, abandoned; 07/201,762, abandoned and 180,548, abandoned. All antibody incubations lasted 60 minutes at room temperature and were followed by three rinses in PBS (0.14 M) NaCl, 2.7 mM KCl, 8 mM Na2 HPO4 and 8 mM KH2 PO4 pH 7.2). In the double-lable experiments with nestin and tubulin antibodies the ST15A cells were briefly rinsed in PBS, presoaked in microtubule stabilizing buffer (MTSB=2 M glycerol, 0.1 M PIPES pH 6.9, 1 mM MgSO4, 2 mM EDTA) for 2 minutes and then fixed for 5 minutes in 4% paraformaldehyde, 0.5% NP-40 in MTSB for 5 minutes. After two brief rinses in PBS and 5 minutes incubation in blocking solution (0.75% Triton X-100, 500 ug/ml bovine serum albumin, 1% horse serum and 0.05% sodium azide), the cells were incubated with a polyclonal rabbit-antitubulin antiserum (kind gift of Dr. Frank Solomon) diluted 1:10000 in PBS. This was followed by an incubation with a fluorescein-conjugated goat-anti-rabbit IgG antiserum (Cappel, No. 1612-0081) diluted 1:100 in PBS. The cells were then postfixed in 95% ethanol/5% acetic acid for 5 seconds and rinsed three times in PBS. This was followed by an incubation with undiluted hybridoma supernatant from the monoclonal mouse-anti-nestin anti-body (Rat 401). Finally, the cells were incubated with a rhodamine-conjugated polyclonal goat-anti-mouse IgG antibody (1:100 dilution, Cappel No. 2611-0231). After two brief rinses in water, the cells were covered with Immumount (Shandon) and inverted onto clean glass microscope slides. As control experiments for potential cross-hybridization and spillover between the fluorescein and rhodamine spectra in the fluorescence microscope, the first antibodies (rabbit-anti-tubulin and mouse-anti-nestin) were omitted in two separate experiments under otherwise identical conditions. No cross-hybridization or significant spillover was observed. In the colchicine experiments the St15A cells were grown as above and treated with colchicine at 25 ug/ml for 24 hours followed by fixation and staining as described here.

In the actin/nestin double-label experiments ST15A cells were grown as above and fixed in 4% paraformaldehyde, 0.1% Triton X-100 in PBS for 5 minutes. After blocking as described above, the cells were incubated with 0.16 uM rhodamine-conjugated phalloidin, as suggested by the manufacturer (Molecular Probes). Rinses, postfixation and staining with the nestin monoclonal antibody were performed as described above, with the exception that a fluorescein-conjugated sheep-antimouse IgG second antibody (diluted 1:00, Cappel No. 1606-3152) was used. No cross-hybridization or spillover was observed after omitting the rhodamin-conjugated phalloidin or the nestin antibody. In the cytochalasin B experiments the ST15A cells were treated with cytochalasin B at a final concentration of 10 ug/ml for 60 minutes, otherwise all immunostaining procedures were identical.

In the vimentin/nestin double-label experiments ST15A cells were fixed in 4% paraformaldehyde, 0.1% Triton X-100 in PBS for 5 minutes. After blocking, the cells were incubated with a polyclonal goat-anti-vimentin antiserum (dilution 1:20, MILES 65-794) followed by a fluorescein-conjugated rabbit-anti-goat IgG second antibody (dilution 1:100, ICN 65-176). Incubation times and rinsing procedures were as described above. Postfixation and incubation with the anti-nestin antibody were performed as in the tubulin/nestin experiments. No cross-hybridization or spillover was detected after omitting the anti-vimentin and anti-nestin antibodies, respectively. In all experiments the mounted cells were photographed on Kodak Ectachrome 400 ASA using a 63X objective on a Zeiss fluorescence microscope.

EXAMPLE 2 Production of the Rat 401 Monoclonal Antibody

Developing monoclonal antibodies were generated to fixed spinal cord from embryonic day 15 (E15) rats. Timed pregnant female rats were obtained from Taconic Animal Supply Co. and housed until the appropriate gestation age. Uteri were dissected from pregnant animals into ice-cold phosphate buffer (pH 7.4), individual enbryos were removed and the spinal cord was dissected free of other tissue into fixative (4% paraformaldehyde in 0.1 M phosphate buffer).

The immunization and fusion protocol has been described previously (McKay and Hockfield, Proc. Natl. Acad. Sci. USA 79: 6747-6751 (1982)). Briefly, BALB/c mice received two intraperitoneal immunizations with fixed tissue homogenized in saline and suspended in an equal volume of Freud's complete adjuvant and a final intravenous boost of unfixed tissue with adjuvantSpleen cells from immunized mice were fused with NS1 myeloma cells and resulting hybrid cell lines were screened immunohistochemically on 100 μm-thick Vibratome sections of 4% paraformaldehyde-fixed E15 rats. Lines producing antibodies of interest were cloned in soft agar or by limiting dilution and antibody subclass was determined by the Ouchteriony method (Ouchteriony and Nilsson, Immunodiffusion and Immunoelectrophoresis. In Handbook of Experimental Immunology D. M. Weir, ed., Blackwell Scientific Publications, Oxford (1978).

Immunohistochemistry

Tissue for immunohistochemistry was fixed either by intravascular perfusion or by immersion. All postnatal material was fixed by intravascular perfusion (under ether anesthesia) with 4% paraformaldehyde at pH 7.4 for light microscopy or with either 4% paraformaldehyde at pH 10.0 or 4% paraformaldehyde, 0.1% glutaraldehyde at pH 7.4 for electron microscopy. The CNS was dissected out and stored in 0.1 m phosphate buffer (pH 7.4) with 0.1% sodium azide. For prenatal material, pregnant females were ether anesthetized, uteri were dissected into cold 0.1 m phosphate buffer and the females were killed by cervical dislocation. Embryos were dissected individually into Sylgard-coated Petri dishes and pinned in place. Intravascular perfusion was performed by opening the skin of the thoracic cavity, nicking the right atrium with a fine forceps and placing a 25 gauge needle into the left ventricle. One to 5 ml of fixative (as above) were injected into the heart. The embryos were placed in a vial containing the same fixative for 4 hr and then stored in phosphate buffer. E12 to term embryos were fixed by perfusion (using a 30 gauge needle for E12 embryos); E10 and E11 embryos were fixed by immersion in fixative. E13 and older animals were sectioned at 50 to 100 μm on a Vibratome without additional support. E10 to E12 embryos were embedded in 15% gelatin before sectioning

Immunohistochemical reactions were performed on free-floating sections by sequential incubations in monoclonal antibody as full-strength supernatant (12 to 20 hr); horseradish peroxidase (HRP)-conjugated goat anti-mouse antibody at a dilution of 1:100 in tissue culture medium with 10% serum; and 3.3'-diaminobenzidine (DAB; 0.025%) with H2 O2 (0.002%). Peroxidase-conjugated lectins (Sigma Chemical Co.) were used at serial dilutions in the same manner with the omission of the peroxidase-conjugated goat anti-mouse antibody. For light microscopy, 2% Triton X-100 was included in both antibody solutions. For electron microscopy sections carried through this procedure (without Triton X-100) were post-fixed in 2% O2 O4 embedded in Epon/Araldite between plastic coverslips, and cut at 1 μm and 0.12 μm for correlative light and electron microscopy. For high resolution light microscopy, sections (Triton-treated) were embedded in plastic as for electron microscopy and sectioned at 2 μm.

Immunoblots

The apparent molecular weights of antigens recognized by antibodies were determined using the method of Towbin et al., Proc. Natl. Acad. Sci. USA 76: 4350-4354 (1979)). Proteins were extracted from unfixed tissue with sodium dodecyl sulfate (SDS) and β-mercaptoethanol and run on an SDS-polyacrylamide gel. The proteins were electroblotted onto nitrocellulose paper which was then exposed to primary (1 hr) and secondary (1 hr) anti-bodies. HRP was visualized with 4-chloronaphthol.

EXAMPLE 3 Chacterization of Rat Nestin from the ST15A Cell Line

ST15A cells were derived from rat postnatal day 2 cerebellum after infection of a primary culture with a retrovirus transducing the temperature sensitive, tsA58 allele of SV40 T antigen (Frederiksen et al., 1988)). ST15A cells were plated on tissue culture plastic coated with polyornithine and passaged at the permissive temperature, 33 C., in Dulbecco's modified Eagle's medium (DME) supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate and 15 mM HEPES, pH 7.2, containing 10% fetal calf serum (FCS). For the experiment in FIG. 8, confluent cells (labelled `day 0`) were transferred into DME/10% horse serum (HS) and cultured at 33 C. or 39 C. as marked for the indicated time. 39 C. is the non-permissive temperature for tsA58.

Primary cultures were prepared from P4 rat cerebellum as previously described (McKay, R. D. G. et al., Cold Spring Harbor Symp. Quant. Biol. (1990). Briefly, tissue was dissociated by trypsinization followed by trituration. Cells were plated on polyornithine-coated coverslips in DME/10% FCS/10% HS and grown at 39 C. for 24 hours. The medium was changed to DME/10% HS and culture continued for 6 days.

The medulloblastoma cell line was derived by growing cells from dispersed, fresh medulloblastoma tissue. The tissue was removed from a previously untreated tumor in a 10 year old female. The cell line has not been cloned. Cells were passaged in Ham's F12 supplemented with 20 mm L-glutamine and 10% FCS.

Immunocytochemistry

Cells for immunocytochemistry were fixed in 4% paraformaldehyde buffered with 50 mM sodium phosphate, pH 7.2, for troponin staining or buffered with 50 mM sodium borate, pH 9.5, for nestin staining. The antibodies used were mouse monoclonal Rat 401 (Hockfield and McKay, supra (1985), mouse monoclonal antibody against troponin T (Sigma T-6277), and rabbit polyclonal serum raised against the C-terminal region of nestin expressed in bacteria. Fixed cells were incubated in primary antibody for one hour, rinsed 3 times in PBS, incubated for one hour with flourescein-conjugated goat anti-rabbit serum (Organon-Tetnika) and mounted in Immumount (Shandon, Inc.) with 2% DABCO. Medulloblastoma tissue and normal human cerebellum were frozen and subsequently fixed in formalin. 50 um sections were cut and stained with rabbit polyclonal serum raised against the C-terminal region of nestin.

Isolation of RNA and Northern blotting

Cultured cells were scraped into 5M guanidine thiocyanate/25 mM citrate, pH 6.8/ 0.5% N-lauryl sarcosine/0.1 β-mercaptoethanol and RNA pelleted through a CsCl step gradient (Chirgwin et al., 1979). 20 ug of total RNA was electrophoresed through a 1% agarose/2.2M formaldehyde gel and transferred to nitrocellulose. Prehybridization and hybridization were in 50% formamide/5xSSC/5X Denhardt's/0.1% SDS/0.1 mg/ml salmon sperm DNA at 42 C. Filters were washed in 2xSSC/0.1% SDS at room temperature and in 0.1xSSC/0.1% SDS at 55 C. and exposed to X-ray film with an intensifying screen. Filters were stripped by washing 6 times for 3 minutes each in boiling 0.05xSSC/0.1% SDS/20 mM EDTA, pH8, and rehybridized. Probes were prepared for hybridization by random priming on fragments isolated on low melting temperature agarose gels (Feinberg and Vogelstein, supra (1984). The following plasmids were used to generate probes: mouse myoD1 cDNA pEMC11s (Davis, R. L. et al., Cell. 51: 987-1000 (1987); mouse myogenin cDNA p65 (Wright et al., supra (1989); rat nestin cDNA p401-16; human B-actin cDNA (Gunning, P. et al., Mol. Cell. Biol. 3: 787-795 (1983)).

Western Blotting

Proteins were extracted from cultured cells or rat postnatal day 5 limb muscle (Sprague-Dawley; Taconic, Inc.) in the presence of aprotinin and PMSF in 2% SDS, 5 mM EDTA and 15% glycerol in 0.1M Tris, pH 6.8. 50 ug of total protein was run in each lane of an SDS reducing gel according to Laemmli (Laemmli 1970); proteins were transferred to Immobilon P membranes (Millipore) using a Hoeffer transfer appartus at 50 volts for 4 hours. Filters were blocked in 5% BLOTTO (Johnson, D. A. et al., Gene Anal. Tech. 1: 3-8 (1984)) overnight. Rat 401 hybridoma supernatant was used undiluted; troponin T antibody was diluted 1:500; polyclonal anti-nestin antiserum was diluted 1:1000; HRP conjugated secondary antibodies were purchased from BioRad.

EXAMPLE 4 Characterization of Human Nestin

To characterize human nestin, a new antiserum, designated anti-nestin 129, was raised to recombinant rat nestin expressed in E. coli since the rat-401 mAb failed to recognize human nestin in immunohistochemical and immunochemical assays.

Production of Anti-nestin Antiserum

The insert from the clone λgt10 401:16 (Lendahl, U. et al., Cell 60: 585 (1990)) was isolated and ligated into the pATH1 vector (Tzagaloff, A. et al., J. Biol. Chem. 262: 17163 (1986)), producing a clone in which the bacterial TrpE protein (37.2 kD) was fused at its C terminus with the last 1197 amino acids of nestin. The fusion protein was induced in E. coli strain HB101 with 20 μg/ml indoleacrylic acid (Sigma I1625) for 4 hours as described in (Tapscott, S. et al., Science 242: 405 (1988)). The TrpE-nestin fusion protein migrates at greater than 200 kD in 6% SDS PAGE gels, making it the largest protein in the bacterial lysate. The fusion protein was purified by cutting the top band from the gel. Anti-nestin antiserum 129 was produced by injecting the fusion protein subcutaneously into a female NZW rabbit. The characterization of anti-nestin 129 and its specificity for human nestin is described here.

First, this antiserum was compared to the Rat-401 MAb in immunochemical and immunohistochemical studies of postnatal day 6 (P6) rat cerebellum. Then, anti-nestin 129 was used to probe human CNS tissues, tumors and tumor derived cell lines. To determine if nestin co-localized with other IF proteins, double and triple immunofluorescence experiments also were performed using anti-nestin 129 and antibodies to vimentin, glial fibrillary acidic protein (GFAP) and neurofilament (NF) triplet proteins. Finally, Western blots were performed on cytoskeletal extracts of some of the tumor derived cell lines to identify human nestin and to compare it with rat nestin as well as with the class III and IV IF proteins expressed by CNS cells.

Specificity of Anti-Nestin 129 in the Rat

The rabbit anti-nestin antiserum produced as described herein, i.e. anit-nestin 129, yielded results identical to those produced by the Rat-401 MAb when both were used to probe P6 and adult rat CNS tissues by immunoblots and immunohistochemistry. On immunoblots of cytoskeletal extracts from P6 rat cerebellum separated by SDS-PAGE, anti-nestin 129 identified a band with an apparent Mr of 240 kD. This band was identical to the band labeled by Rat-401. Further, both antibodies labeled similar bands in lysates of the induced bacteria producing the TrpE-nestin fusion protein.

In immunohistochemical studies of the P6 rat cerebellum, anti-nestin 129 labelled radial glial cells very intensively. The processes of these cells radiated from the internal granular layer to the external granular layer. These radial glia also were labeled with Rat-401 and the anti-vimentin MAb. Neither of the anti-nestin antibodies stained immature Purkinje cells or other neurons. In contrast to the P6 rat cerebellum, the anti-nestin 129 and Rat-401 antibodies only stained blood vessel endothelial cells in the adult rat cerebellum, while the anti-vimentin MAb (V9) labelled blood vessels, white matter astrocytes and radial glial fibers. Furthermore, nestin immunoreactivity was demonstrated by both anti-nestin antibodies in immature skeletal muscle of the P6 rat as well as in Schwann cells of adult rats (data not shown).

These studies demonstrate that this new anti-nestin antiserum yields immunohistochemical results in the human developing spinal cord, cerebrum and cerebellum that were nearly identical to those produced by Rat-401 and the anti-nestin antiserum in the rat.

EXAMPLE 5 Cloning of the Human Nestin Gene

The human nestin gene (SEQ ID NO: 3) was isolated using low-stringency DNA hybridization of a human genomic bacteriophage lambda library with a rat nestin probe.

A genomic library in the vector EMBL 3 made from partially Sau3A-digested human genomic DNA (Clontech) was screened using a 32 P-labelled probe derived from the rat nestin gene starting at 202 nucleotides upstream of the translation start and ending at nucleotide 483 after the translation start (Lendahl, et al., 1990) under the following conditions: prehybridization in 6X SSC, 5X Denhardt's solution, 0.5% SDS and 100 micrograms/ml salmon sperm DNA at 65 C. for 1 hour; hybridization in the same conditions except for using 50 micrograms/ml salmon sperm DNA and hybridizing for 16 hours. The filters were then washed for 230 minutes at 48 C. in 2X SSC and 0.25% SDS.

One positive clone out of 1.5106 placques screened contained the entire human nestin gene and was chosen for further analysis. This clone was purified and grown in large scale (Maniatis, et al., 1989). A restriction map was established and EcoRI fragments were subcloned in the plasmid vector Bluescript KS I (Stratagene).

EXAMPLE 6 Nestin Expression in Brain Tumor Samples

Immunohistochemical data on the expression of nestin, other IF proteins and synaptophysin (SYP) by a diverse group of 34 CNS tumors are summarized in Table 2.

                                  TABLE 2__________________________________________________________________________Immunoperoxidase staining of brain tumorsNo.           Age (Yr)               Sex                  Material                       Location    Nestin                                       Vim   GFAP  NP SYP__________________________________________________________________________PNETsPNET + N,G1             1     M  F    posterior fossa                                   +   +++   +     +  -2             1     M  F    posterior fossa                                   +   +++   +     +++                                                      +++3             5     F  F    posterior fossa                                   ++  +     +     +  ++4             1     M  F    posterior fossa                                   ++  ++    +     +  +++5             1 month               F  F    posterior fossa                                   ++  ++    +     +++                                                      +6             5     M  F    posterior fossa                                   ++  ++++  ++    +  +7             8 months               F  F    posterior fossa                                   +++ +++   ++    +  +8             1     F  F + P                       posterior fossaa                                   ++  ++    +     +  +++PNET + N9             13    F  F    posterior fossab                                   -   ++++  -     ++ ++10            6     M  F    posterior fossa                                   -   +     E     ++ ++PNET + G11            11    M  F    posterior fossa                                   +   +++   ++    P  +12            4     F  F    posterior fossa                                   +++ ++++  ++    P  +++PNET, NOS13            2     M  F    pineal      ++  ++    -     -  ++14            11    M  F    posterior fossab                                   -   +     -     -  ++15            14    M  F    posterior fossab                                   +   +++   -     -  +Astrocytic tumors16            2     F  F    posterior fossac                                   ++  ++++  ++++  -  -17            6     F  F + P                       posterior fossac                                   -   ++++  +++   -18            6 months               M  F    hypothalamusc                                   ++  +++   +++   -  -19            17    M  F + P                       posterior fossad                                   -   +++   +++   -  -20            3     M  F    frontale                                   +++ NA    +     -  NA21            6     M  F + P                       occipitalf                                   +++ +++   +++   -  -22            13    M  F    posterior fossaf                                   +++ +++   +++   -  -Ependymomas23            3     F  F    parietal    ++  ++++  +     -  -24            2     M  F    posterior fossa                                   +   -     +     -  -25            3     M  F + P                       posterior fossa                                   ++  ++++  +++   -  -26            5     M  F + P                       posterior fossa                                   ++  ++++  ++    -  -27            15    F  F + P                       cerebral hemisphereg                                   ++  ++++  +     -  -28            8     F  F + P                       parietalh                                   +++ +++   ++    -  -Choroid plexus papillomas29            1     M  F    posterior fossa                                   -   +++   +     -  -30            2     M  F    lateral ventriclei                                   -   +++   -     -  -Gangliogliomas31            2     F  F    temporal    ++  +++   +++   +  -32            1     F  F    occipital   ++  ++    +++   +  -Meninglomas33            8     M  F    posterior fossa                                   ++  ++    -     -  -34            27    M  F + P                       anterior fossa                                   +   +++   -     -  -__________________________________________________________________________ Legend to Table 2 Summary of the data obtained from the immunoperoxidase studies of each of the brain tumor samples. Results from frozen (F) and paraffin (P) materia are combined in the cases in which both kinds of material were studied. The patterns of staining are described as - = no staining, + = positive in less than 5% of tumor cells, ++ = positive in between 5-50% of tumor cells, +++ = positive in between 50-95% of tumor cells, ++++ = positive in more than 95% of tumor cells, E = positive cells equivocal, i.e. reactive astrocytes of tumor cells, P = interstitial filamentous staining in the neuropil. The following antibodies were used to obtain these data; nestin (rabbit antinestin antiserum 129), vimentin (V9), GFAP (2.2B10), NF (RMS12, RMd020, RMO254, HO14, DP1, TA51, RMO24). NA = not available due to limited material; PNET + N,G = PNET with neuronal and glial differentation; PNET + N = PNET with neuronal differentiation; PNET + G = PNET with glial differentiation; PNET - NOS = PNET, not otherwise specified. a reccurent tumor of case 7, b autopsy case, c benighn astrocytoma d genighn strocytoma + angioma, e anaplastic astrocytoma f glioblastoma multiforme, g mixed ependymoastrocytoma, h anaplastic enpendymoma, i choroid plexus carcinoma.

The results from frozen and ethanol-fixed paraffin-embedded samples from the same biopsy are combined in the 10 cases from which these paired samples were available. Notably, the immunohistochemical results obtained from each of these paired samples were identical, although the primary antibodies were used at slightly higher dilutions in the frozen material compared with the paraffin material.

PNETs The anti-nestin antiserum stained tumor cells in 12 of the 15 PNETs examined here. Nestin immunoreactivity was found in the cytoplasm of individual neoplastic cells. Reactivity was also observed in the coarse processes of large stellate cells, as well as in blood vessel endothelial cells. In the PNETs with an insular architecture, nestin reactive cells were found both within and outside the islands. Since PNETs express SYP and other neuroendocrine markers as well as all classes of IF proteins (Gould, V. E. et al., Human Pathol. 21:245 (1990)), the PNETs were probed for SYP. These studies demonstrated SYP in 14 of 15 PNETs. Vimentin was detected in all the PNETs. Ten of the 15 PNETs expressed GFAP and 10 expressed 1 or more NF proteins. Double immunofluorescence studies of nestin and NF proteins, as well as nestin and GFAP on frozen sections showed their co-localization in the same cells (data not shown). The immunohistochemical data on GFAP and NF proteins suggested that 15 PNETs could be classified into 4 subtypes, i.e. 3 cases of PNET-NOS (not otherwise specified), 2 cases of PNET+G (PNET with glial differentiation), 2 cases of PNET+N (PNET with neuronal differentiation) and 8 cases of PNET+G,N (PNET with glial and neuronal differentiation). All 8 cases of PNET+G,N showed nestin immunoreactivity and 2 cases of PNET+G expressed nestin. On the other hand, 2 cases of PNET+N were negative for nestin. These results may indicate that PNETs with neuronal differentiation tend to lack nestin expression in contrast to PNETs with glial differentiation. This phenomenon paralleled normal differentiation in that postmitotic neuroblasts did not express nestin whereas radial glial cells did, even at relatively late developmental stages. Two of 3 cases of PNET-NOS showed nestin positive tumor cells. This immunohistochemical phenotype might represent primitive neuroepithelial cells or immature radial glial cells in the developing CNS. The other PNET-NOS case was negative for nestin and it might correspond to extremely immature CNS precursor cells just like the most undifferentiated PNET cell line (i.e. Daoy).

Astrocytic tumors Five of 7 astrocytic tumors displayed positivity for nestin in the perinuclear cytoplasm of the tumor cells as well as in the cytoplasmic processes of these cells. Additionally blood vessel walls were nestin positive. Two of 4 benign astrocytomas were negative for nestin. One anaplastic astrocytoma and 2 glioblastomas showed strong nestin positivity. In the glioblastomas, multinuclear giant cells were stained strongly.

Ependymomas Six tumors were histologically diagnosed as ependymomas and all showed nestin positivity. Immunoreactivity for nestin was found in the tumor cells which formed perivascular pseudo-rosetts. One ependymoma (with marked nuclear pleomorphism, necrosis and a few mitoses) was diagnosed as an anaplastic ependymoma and it demonstrated the strongest nestin immunoreactivity among the 6 ependymomas. Expression of nestin described here indicates that nestin is the dominant IF protein of early CNS precursor cells. However, nestin is rapidly extinguished in neurons, glia and other CNS cell types derived from these precursors. The mechanisms responsible for these rapid changes in IF protein expression are unknown.

In contrast to the restricted expression of nestin in normal developing CNS cells, this IF protein was ubiquitously present in a wide variety of CNS neoplasms. Nestin was expressed in a subset of PNETs, but was more abundant in gliomas. The presence of nestin in diverse types of neuroepithelial tumors is similar to vimentin, but distinct from the distribution of GFAP and NF proteins in CNS tumors.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

__________________________________________________________________________SEQUENCE LISTING(1) GENERAL INFORMATION:(iii) NUMBER OF SEQUENCES: 4(2) INFORMATION FOR SEQ ID NO:1:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 11236 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:CGTGTTT GCTTTAGCAAGACGTCTTTTTACCTGTGTACCCCAAAAAACATCATTTGATGT60AACTAACTTACTCAAGGCTATTGAGCCAGAGGGGAAATTCAGAGCCACCAGTGCAAGGCA120CAGTGCCATAAGGGTCATAGTCAAGCACTTGCAGTCTCTTTAGAACATGGTC GGTGCTCA180GAGAAGGATAGAGAAAAGGAAAGATACCCTCTTTGCCCGGAGACCTCCGGCGGGAAAATT240TATATGATCCACAGTAGTGGGTATGTAACAGGCATACAAGCCAAACACTGATAGTCATAA300AGACATTCATGTTAGAACAAATTCTTGGTA TACAGATTATTTTTCCATTTTTAAAAGATG360AAAGAAGCTTTTCCTGCTAATGGGAAGGATCGCTTGTTTATCCTCACGTAGCATTGAATG420TTCTTGGCTGAACATTTGGTATTTAAAACCATGGTAGAACATCTTCAACGTTTTCAGAAT480TGATCCA TACTTTGATTTAAAAAGTAGTTTATTGGGTTGGGATTTAGCTCAGTGGTAGAG540GCTTGCCTGAAGCCAAGGCCTGGTTCGTCCCACGACGTCTCGCAGAAAAAAGAGAAAAGA600AAAAGTAGTTTATTGCTATTTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG TGTGTGTG660TGTGTCTGTGTATGTCTGTGCATGGGCAGTATACCTGTGTGTGGATGCACATAGAGGTCA720GAGGCCTTTGATGTCCCTGGAGCTGATATGGGTGCTGAGAATTGTACTTGGGTCTCCGGG780AGAGCAGCAAGTGCTTTTGACGACTTAGCA TCTCTCCAGCTCAGATATCCTGATTTTCTA840ACTGTCAATGCTGGGAATGCCAATCTGTATGAATGATTCTGCCCACAGCAGAAGTATGTT900TAGGACCATTTCAGAAATTGTTGGAAATTTTGTCCTAATCGTAAGCCAAAATTCACTGAA960GGATTTT ATTTTTCGTTTGAGACAGGATCTTACTATGTAATCCTGGCTGGCCTGGAACTC1020ATTTGCTATGTAGAGGCTGGCCTTAAACTCAGAGATTGGCATTATTCTGTCTCTTGAGTG1080CTGGGATTAAAGGAATTAAACTGGCCTCACTGAACGAGGTTTGATGACACTC AAGTTATC1140GACTCAAACAGCTATTTAAAAGAATTTAGATTTATTACTGTTGTTATTGTTGTTAGTCTG1200TGTGTGTGTGTGTGCGCGCGAGCGCAGGTGCACCATGCTACAGTATGCCATGTGCGAGTC1260AGTTCTCTCCTCACTATGTGGGTCCTGAAC ATCATGGGAGGGAGCTTGGCAACAGGCACT1320ACCGGCACTGAGCAGCGACTCAGAGCTCACATCTCAATCCACTAGCACAAGGCAGAGAAG1380GAGCTACTGCAACCTCTCTCAAAGCCTACCCCCAGTGATACACCTCCTCCAACAAGGCCA1440TTCCTCC CAATCCTTCTAAAATAGGTTCTCCAACTGGGGACCAAGCATTCAAACATTTAA1500GCCTAAGGGTCCCTTGTACAAAGTCCACAACTTCATTTCTTTCTTCGCCAGACTGCATCG1560TTAGCCACCAGGGGGCTCCCCTGAGAGCCGCGTAGCTTTCTAACTGAGTAAA CTGCAAGA1620GTGTACGAACAACAAAGGAGAAAAACTTTCTTGAACGTATGACGTCCCTTGCCATTTTCC1680TTTTCCTGATGCGGGATGAGGAGGGGGAGGACGTCCCTCTGCGGGTACGAACTGTGCATT1740GTGTCTGTTAACATCAACTGGGCTGGCTGG GCAGGGGTGTTGGCACAGACCTTTAATCCC1800AGCACTAGGGAGGCTAAAGCAGGAGCATCTCTACGATTTCGAGACCAGCCTGATTCACAT1860AGCGATACCAACCATCTGAAGAAAGGGGTGGGGGGTGTTTACTGCCCAGGCTGGCCTTAA1920TCCTTCT TCGGGCTTCGGAGCTCAGGAAAACCCAGTACCAGTGGGTTTTTCTTGCTTCGG1980GCAGTGTCTCTCTGCAATGTTGCCTCCCTGGGACAGGTGGTGGTGGTGGTGGTGGTGGTG2040GTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGGTGTGTGAATATTTACTGT TTTACACA2100AAACACTGCACCGTCCGTTTTTCCAACAGTTCATGAGGATTCCAACACCAAGCCATTCTA2160TAAATAAGAAGCCGAGTCTCAGAGAATTTGAGTGTGTAGAGAAAGGAGGTCCGCAGGCCC2220AGTTCTGTGCATCATAGGGTGTTCCGGGGT GTCTGGCTGTATCTCAAGATTCTCTCAGAA2280AATCACCCGCACCGGACCGGATCCCTCAGGGAGGGGCTGCACTTTGGTTCTTCTCTTCTG2340CACCCGGATGAAGCAGGAACCCCGGTTGCGTGTTGCACTGAACGCTAAAGGGTTAAGGCC2400TGGGGGG CCGCCCCTTTTCCGCCCAGCCGGCGGGAGTATGAATACCCTCGCTCCAGCTCC2460CTGCTGGAGTTCTCCGCTTCCGCTGGGTCACTGTCGCCGCTACTTCTTTTCAACCCCTAA2520AAGCTCCACGGGCCACTCCCTTCTCTAGTGCTCCACGTCCGCTTGCCCTCGG GGGCCAGA2580CCAGCGACATGGAGGGTTGCGTCGGGGAAGAATCTTTTCAGATGTGGGAGCTCAATCGAC2640GCCTGGAGGCCTACCTGACCCGGGTCAAGACGCTAGAAGAGCAAAACCAGCTGCTCAGCG2700CCGAGCTTGGGGGACTCCGGGCGCAGTCCG GAGACACCTCCTGGAGAGCCCGAGCCGATG2760ACGAGCTGGCATCCCTGCGGATCCTCGTCGATCAGCGCTGGCGGGAGAAGCTCGAGGCTG2820AGGTGCAGCGCGACAACCTTGCGGAAGAGCTGGAGAGCGTGGCGGGCCGGTGCCAGCAGG2880TGCGGCT TGCTCGGGAGCGGACCGTCCAGGAGGCCGCCTGCAGCCGGCGCGCACTCGAGG2940CGGAGAAGAATGCGCGGGGCTGGCTGAGCACCCAGGCGGCCGAGCTGGAGCGGGAGTTAG3000AGGCTCTGCGAGCCGCGCACGAGGAGGAGCGCGCACACCTGAACGCCCAGGC CGCCTGTG3060CGCCTCGCCGGCCCCCCGCACCGCCCCACGGATCCCCGGTCCGGGCCCCCGAAGTCGAGG3120ATCTGGCCAGGCGACTAGGCGAAGTGTGGCGCGGGGCGGTGCGTGACTACCAGGAGCGCG3180TGGCTCACATGGAAAGCTCGCTGGGTCAGG CACGCGAGCGGCTGAGCCAAGCCGTGCGGG3240GCGCTCGGGAGTGTCGCTTAGAGGTGCAACAGCTGCAGGCTGATCGCGACAGCCTCCAGG3300AGCGCAGAGAAGCGCTGGAACAGAGATTGGAAGGCCGCTGGCAGGACCGGCTGCAGGCCA3360CTGATAA GTTCCAGGTGAGGAGGGTCACCAACTTCCTCCCCGACTACCCGCCCCCACACA3420GACCCGTAAGACCAAGCCCTAGGAAGTACTTAGGATGGCAAGAGACCTTCAGGAAGGGGC3480TGGAGGAAAGGGCGACTGTATTCATGAGTCCTGCCCAGAGCAAGCACAGGCC CTAAACTT3540TCCTGTCCAAGCAGGATGGGCGGATGGAATTCTGAGACCTCCTTAGCAGAGCCCGCTTAA3600AGGACGACAGGCCAATTCCCACTGTAGCAGCTCCTCACTCTTTGAAGGGCAATTTCACTC3660TAGGATGATTCCCTGCGCCCTTCCCTTTGC TGTTGTCAATCAGAAGGTGCCCAGCACATG3720CTCCCTCAGCACCAGAAGGTCCCTAGCAACCATAGTGAAGGAAGGCGGGGTGAGCCACCG3780CCGACCACCAGCCCCTCTCTGTGTCAAGGCTTCTCAGCTCCCTGAAGCACATTCCAAAGG3840CCTGGGG CACCCTCCCCCTTATACTGCACAGATGTAACCAACAGCTGAGAAAACAGCTCT3900TGCCTGGCCCAGACAGAAGCCCCGACACGGCCATCTGCCCACTCTTCTTGGGGGAGAAAG3960ATTCCAGAACACGTGGGAAGTGGAGGAACCCAGCCTGCTATGAGGAGCTGGG GACAGTGA4020TGGCCAACGGATTTCCTTCCACGTCCTCCCAAGCCGACTCTTGATAAATTGCTTTTCCCT4080TCTGTTTCCATTTTACCTCCTCTTCTGCTGTGTAACCCATCCCCGTGGGAGCTAGATTCT4140CAATAGCATGTGTTACCATTTAATGAGCAT CCTCAAGAGAAGCCTGGTCTAGGAGAGGCA4200TGGAGTGTTCCCTGAGCTTGTCTGTGGGTTCCAGTGCAGGGAGGACATAGAACAGGAGTC4260CTACAGAGAAGTGAGCAGTAAGGAGCCTCAGGGCCAGAGCGGAGGCTCCTTCCACTCACT4320CTTCCCG CTTGCCTTGCAGCTGGCTGTGGAAGCCCTGGAGCAGGAGAAGCAAGGTCTACA4380GAGTCAGATCGCTCAGATCCTGGAAGGTGGGCAGCAACTGGCACACCTCAAGATGTCCCT4440TAGTCTGGAGGTGGCTACATACAGGTACACAGTGCTGACTGTCCTCGGCTTC TTCTGCGG4500CCCAGAAACTTGGCTTTGTACTTTCTGTGACTGTCAGCTATCGCTTTGTAAAACTGTCCT4560ATTTATGTGTATTTGTGTATGTACCACATGTGTACAGGTGTCCTAAGAGCCCAGAGGAAG4620GCAATGGGTTGTGTGCAGCTCCACACTGGT GCTGTGAACCAAACCCCTGTTCTCAGCAAA4680AAGCAGCAAGCATTCTTAACCACTGAGCCGTCTGTCCAGCCCTCGGAGTCACTTAAAACG4740TTTTATAACATTTACTTATGTAATGTATTTGTCTGGGATGGAGGCTTATGAGTCCCAGAG4800GTGGAAC AGGTCTGGCTTGGCAGCTTGGCCCACCCAGGCCCAGGACCAGAAGAGAGCGGT4860GATGCTTAAAAAGACAGCTCAGTCTTCAGGGAGGAGACCAGACAGATGAGTTCTTTGGAA4920GGCAGGCAATCTCCAGTGTCTATGCCAACATCCTGGGGACACCTGGGCAGTC TCAGAAGA4980GAGGCCTTGCAGGTTTGCCTGATCATGCTAACCTGCCACCTCGCCTGGGCCTCAGGTGTT5040TTGGGTAAGAGCTGGCCTCCTAGCTTTTTTGCTTCCTTTCAAGCCCTCATGTCACTGGTC5100CTGCCCCAGTTCTCTGCCCTTTTCTTGGCT GCCTCAGGACGGCTGAGTGGAACGGCTCTG5160GTGGTATGTTCACAGCCTCTGTCTGTGTCTCTTGTGGGAAAAGGCCCCAGTTGGAGTCCC5220ACGGTTGAGGGCTGAGGATATCACTCCAGGTATGGGCTAGGACAGGATGCCCCCCTTTTC5280CAGAATC CAGCGGTAAAGAGGAAAGACAGAGACAGGTCTAGGAGAGGAGCTGGAGGGCCC5340AGAGAAGGACAGCCAGTGAGTGTCTAGGAAAGACTGAATGCATAAGGCAGGATGCCGCAT5400GAGGACAGAGGAAAGGCTACTTTGAGAACCAGATGTGCTCAGAGGCCATGAA TGGAAACA5460GACTAGTTCCGAATCCCATGTGAACTGATTTCCCTCATCTCCTTCAATCAGCTCCATAGG5520CCACTGAGGCAGGGCCATGAACGTTAAGACCTCTGCCCTGAAGAGTTTGTGATCCTGAGA5580TGAGGGCTTTAGCCCCAGTCAGTCCTCTGA GGGGAAGGGTCCAGGCAGCTCTGAGGAATG5640TAACCACTGGCGTTTGAGGTCTGAAAAGGATTTGGAGAAGGGGAGCTGAATTCATTTGCT5700TTTGTCTGTTACCAGCTCTGGGGGCAGAGAGAGAGCCATCCCCTGGGAACAGCCTGAGAA5760TTCCCAC TTCCCCTGAGGAGCCCTCCCTTCTTAGGCCCTCCAGATGGTAGTGTGGACAAA5820AGGCAATAATTAGCATGAGAATCGGCCTCCCTCCCAGAGGATGAGGTCATCGGCCTTGGC5880CTTGGGTGGGGAGGCGGAGACTGATCTGAGGAGTCTGATATAAGTGTTAGCA ATTCATTT5940GGCCCTGCCTCCGACTGTGGGAATCTGCATGTGGGGTCTCCCTGTGTCTCAAATATGGGT6000TGGCTAAGTATATATCTGTGTGGCTTTTATATGACAATGGTCACAATAGAGATTGATCCT6060GCAGTGGCAGGACATGCTACCTCAGCTGGA GCTGACCCTATCTCCCCACTCCCCACCAGG6120ACTCTGCTGGAGGCTGAGAACTCTCGGTTGCAGACACCTGGACGAGGTTCCCAGGCTTCT6180CTTGGCTTTCTGGGTAAGAGGCGGAGCCTAACTGCTCTCCTTGGAAGATCTTCCCTAAGC6240AGCATCA GTCTAAGCCTTCATTCCCTGGTCCCAACCCTACTGATGTTCTCAGTCTAGCCA6300GTGGGGGTCAGACAAAATGACCAATGTGAGAACTGCTCTGGGCTGAGGTCAGGACATACT6360TACAGTGTTTCTTACTCTGCTTTTCCAGACCCCAAGCTGAAGCCGAATTTCC TTGGGATA6420CCAGAGGACCAGTACCTGGGATCTGTGCTCCCTGCCCTCAGCCCCACATCCTTCCCTTCC6480CCCTTGCCTAATACCCTTGAGACTCCTGTGACAGCCTTCCTGAAGACTCAGGAGTTCCTT6540CAGGCCAGAACCCCCACCTTGGCCAGCACT CCCATCCCACCTATATCTGAGGCTCCCTGT6600CCTCCAAATGCAGAGGTGAGAGCCCAGGAGGTCCCTCTTTCTCTGCTCCAGACACAGGCT6660CCAGAGCCCCTTTGGCTGAAGGCCACAGTGCCTAGTTCTTCTGCTATCCTCCCAGAACTA6720GAGGAAC CTGGGGGCAAGCAGCAGGGTCACTTCCCTGATGATCTGACCTCCTTAGCCACA6780AACCTCAACCCTCACCACCCTACTTTAGAGGCTAAAGATGGAGAATCCAGTGAGTCTAGA6840GTTTCTAGCATATTCCAGGAAGATGAGGGGCAAATCTGGGAACTGGTAGAGA AAGAAGCA6900GATATAGAGGTAAAAGTAGAAAACAGCTCAGCCCAGAAAACACAAGAAAGTGGTCTGGAC6960ACAGAAGAAACCCAGGATTCCCAGGGACCTTTGCAGAAGGAAACACTGAAGGCTCTAGGA7020GAGGAGCCACTGATGTCTCTGAAAATCCAG AACTATGAGACAGCAGGGAAAGAGAATTGC7080AATTCTTCTACAGAAGGCCACCTGGGAACACTAGAAGGCCCAGAAAAAGAAAAGCAAATA7140CCACTAAAGTCTTTAGAAGAAAAGAATGTAGAGTCAGAGAAAACTCTAGAAAATGGGGTT7200CCTGTAC TATCTGAGCTTTTAGGAAAAGAAGACACAAGAACAGAGGATCAAGAATTAATG7260TCTCCTAAAGGTACACTAAAGAGATTTTCATCTCTAGGAAAGGAAAGTCAAGAAGTAGTG7320AGGCCTTCAAAAGAGGGGAACCTAGAATCATGGACAGCTTTTAAAGAGGAGA GCCAACAC7380CCACTGGGATTTCCAGGAGCTGAGGACCAGATGCTTGAGAGACTGGTAGAGAAAGAGGAT7440CAGAGCTTCCCAAGGTCTCCAGAGGAAGAGGACCAGGAGGCATGTAGACCTCTGCAGAAA7500GAGAATCAGGAACCACTAGGGTATGAAGAA GCAGAGGGCCAGATACTTGAGAGACTGATA7560GAAAAAGAGAGTCAGGAGTCCCTGAGGTCTCCAGAAGAAGAGGACCAGGAGGCAGGTAGA7620TCTCTGCAGAAAGAGAATCAGGAGCCACTAGGGTATGAAGAAGCAGAGGACCAGATGCTT7680GAGAGAC TGATAGAAAAAGAGAGTCAGGAGTCCCTGAAGTCTCCAGAAGAAAACCAGAGG7740ATTGGGAAGCCTCTAGAAAGAGAGAATCAGAAATCTCTGAGGTATCTTGAAGAAAACCAG7800GAGACTTTTGTACCACTAGAAAGCAGGAACCAGAGGCCACTGAGATCTCTAG AAGTAGAA7860GAGGAGGAGCAGAGAATTGTGAAACCTCTAGAAAAAGTGAGTCAGGATTCCCTCGGATCT7920CTAGCAGAAGAGAATGTGCAGCCACTGAGGTATCTGGAAGAAGATGACTGCATAAATAAG7980AGCCTTCTAGAAGACAAGACTCACAAGTCC TTGGGGTCTCTTGAAGATAGAAATGGGGAT8040AGCATTATTATACCACAAGAAAGTGAGACCCAGGTTTCATTGAGGCCTCCAGAAGAGGAG8100GACCAGAGGATTGTGAACCATCTAGAAAAAGAAAGTCAGGAGTTCTCGAGGTCTTCAGAA8160GAAGAAG AGCAGGTGATGGAGAGATCTCTAGAAGGAGAGAACCATGAATCACTGAGTTCT8220GTAGAAAAAGAGGACCAGATGGTTGAGAGCCAACTAGAGAAAGAGAGTCAGGACTCAGGG8280AAGTCTCTTGAAGATGAGAGCCAGGAGACCTTTGGACCTCTGGAAAAAGAGA ATGCAGAG8340TCCCTGAGATCTCTAGCAGGACAGGACCAAGAGGAACAGAAGCTTGAACAAGAGACCCAA8400CAAACACTGAGGGCTGTAGGGAATGAGCAGATGGCAGTGAGCCCACCAGAAAAGGTGGAT8460CCAGAGTTACCGAAGCCTCTTGGAAATGAC CAGGAAATAGCTAGATCTCTTGGAAAAGAG8520AATCAAGAGTCACTAGTGTCACTGAAAGAAAAAGGTATAGAGACAGTGAAGTCTTTAGAA8580ACAGAGATCATAGAACCACTGGAGACTGCAGAAGAGGACCTGGAAAGAAGGAAGTCTATA8640GATACTC AGGAGCCATTGTGGTCTACTGAAGTGGCTAGAGAGACAGTAGAACCTCCAGAA8700GATGAGCCCCCAGGATCGCTAGGGTCTGTGGATGAGAACCGAGAGACACTGACATCCCTT8760GAAAAGGAGAGTCAAGAACTGAGCTCTCTGGGCAAGTGGAACGTAGAGACCA GGGTAGAG8820GACAGTCAGCAGTGCCTGCAAGTAGAAGAGGGTCTGCAGGAGGAACAGCACCAAGAGTCT8880CTGAGAGAGGTGAAGCAGGAGCTGCCTAGCTCTGGAAATCAACAGCGGTGGGAGGATGTG8940GTGGAGGGCAAAGCAGTGGGTCAGGAAGCA CCTCTGGCAACCACAGGAGTGGGAACTGAG9000GATAAGGCAGAGTTGCATCTGAGGGGGCAAGGTGGAGAGGAAGAAGCTGCAGCAGAGGGA9060GAGCTGTTGCAGGATATTGTGGGGGAGGCCTGGAGTCTGGGGAGCTCTGAGCCCAAGGAG9120CAGAGGG TCCCTGCTGAGGCCCTCGACAACCTGGAAGGAGGGGCCTTAGAGGTCCCAGTT9180GCTCAGTCAATGCCAGAGGTGACAGAGCGAGATGAGGATAGAGCCCAAGCAGGTGAACAA9240GACTCCATAGAGGTGACCCTTGGGTTAGAGGCTGCCAGAACTGGACTGGAAC TCGAGCAG9300GAAGTGGTAGGGCTAGAGGACCCAAGGCATTTTGCCAGGGAGGAGGCCATTCCCCCATCC9360CTGGGGGAGGAAAGTGTGAAGGCAAAGATAGCTCAGGGCTTGGAAGGGCCTGGAAAGGAA9420CCAAAAGAGGCAGGTGCTCTGGACTCGGGG ATCCTTGAATTGCCCAAGACTAGCAGCGAG9480GCTCTGGAATGCCAGGGCCATGAAGAGTCTGAGTCCATGGAGGGCTGGGAAGAAGAGGAG9540GCCTCACTGGAGACTTCAGATCATGAGGGCAGTGATGCCCCTCAGCCCAGGCCCCCAGAA9600ACAGAAG AAGATGAGGGTGCACAGGCAGCACTGACAGCCCCTGGTCCCAAGCTCTTGGAA9660CCCTGTTCACCCATCCCAATCCTGACAGATGCCCATGAGCTGCAGCCCCAGGCTGAGGGG9720ATCCAGGAGGCTGGCTGGCAGCCAGAAGCTGGGTCTGAAGCACTAGAAAGGG TAGAAAAT9780GAGCCAGAGTTTGGTCTTGGGGAGATCCCGGAGGGCCTCCAGGATTGGGAAGAGGGCAGA9840GAAGAAAGCGAGGCAGATGATCTAGGGGAAACTCTCCCTGACTCTACTCCCCTGGGCCTC9900TACCTGAGGTCCCCTGCTTCTCCAAAGTGG GATCTGGCTGGAGAACAGAGGCTTTCCCCT9960CAAGGGGATGCCGGGAAGGAAGACTGGGGTCCTGCTGTCCCCGCTGCCCAGGGCCTCAGT10020GGTCCACCGGAAGAGGAGGAGGAGCAAGGCCATGGCTCTGACCTATCATCTGAGGAGTTT10080GAGGACC TAGGGACTGAGGCCTCTCTTCTTCCAGGGGTTCCCAAGGAGGTGGCAGATCAC10140GTGGGCCAAGTGCCCCCGGTACTGCAGCCTGCATGCTGGGATCAGGGTGGGGAATCTGAT10200GGGTTTGCTGATGAGGAAGAAAGTGGGGAGGAGGGAGAGGAAGAAGATGCTG ATGAGGAA10260GGAGCAGAGTCAGGAGCTCAGTGGTGGGGGTCAGGGGCCTCTGGTGGAGGCTGCAAGGTC10320CAGGATATTGCCCAAAGAGGAGACCCGGTACAGGAGTCTGTGGGTGTCAGTGGTCTCTGG10380GATGATGGCTTGAGAGGTGCTGCAGCTAAT GTTCCTGCCCTAGAGATGGTATCTCAGGAC10440AGTGCTGAGCCTTCTGGGTCAGAGGAGTCTGAGTCTGCTTCCTTGGAGGGGGAGGAAGGT10500CAAGTGACTGACCATTTAGATGCTCCCCAGGAGGTGACCAGCATGGTCCCGGGGGTAGGA10560GATGCCT TTGACATTGGTGGCCAGAGCCCCAACTTGGACTCAGAACAAGTGAATGGGAAA10620ATGGAGAATGGACTAGAACAGGCTGAGGGGCAGGTGGTCCTGGATGGGGACGAGGATCAA10680GAACTCCTATTACAGGGACAGGAGGTGGGTGCTCTAAAGGTTCCTTTGGTAG CATCTCCT10740GTGCATCTAGGCCCAAGCCAGCCCCTGAAGTTCACTCTGAGTGGGGTAGATGGGGATTCC10800TGGTCCTCAGGGGAAGACTAGAAACTGCCCCTCTGGCTCTGAGGATGTACTGGTGGGGAT10860GTCCCTCCCTGCTCTGGGTGACCACTCTTA GCTTTGATAACTTGACCCATGGTATTTGTC10920CTGGAGAGTTGTGGCTGGGCTGAGCAAGGGAGGTGAGATCCTCCTGAAGGCTCAGGAGTT10980CCAGGCCTATAGTTCTACCCCCTCTTTCTTCTGTGGCTCACCTGCTGGAAGAGGCCTGGG11040CCCAGAG CTTTCCCACAAGGCTGTTCTGGCCACAGCTTGCTAGCCTTGCCTACCACCTGC11100ACAAGGTCTGGTCTGGTGTATGACCAGGGGAGCTGAGGGCAGCATTTATCTGACCCTTCA11160TCTCAGCCTGCTGAGAGCTTGTTCCTCTCTTCCTCCCTGAATAAAGCCGTAT CCCTACCT11220ACAAAAAAAAAAAAAA11236(2) INFORMATION FOR SEQ ID NO:2:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1805 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:MetGluGlyCysValGlyGluGluSerPheGlnMetTrpGluLeuAsn151015ArgArgLeuGluAlaTyrLeuThrArgValLysThrLeuGluG luGln202530AsnGlnLeuLeuSerAlaGluLeuGlyGlyLeuArgAlaGlnSerGly354045 AspThrSerTrpArgAlaArgAlaAspAspGluLeuAlaSerLeuArg505560IleLeuValAspGlnArgTrpArgGluLysLeuGluAlaGluValGln65 707580ArgAspAsnLeuAlaGluGluLeuGluSerValAlaGlyArgCysGln859095 GlnValArgLeuAlaArgGluArgThrValGlnGluAlaAlaCysSer100105110ArgArgAlaLeuGluAlaGluLysAsnAlaArgGlyTrpLeuSerThr 115120125GlnAlaAlaGluLeuGluArgGluLeuGluAlaLeuArgAlaAlaHis130135140GluGluG luArgAlaHisLeuAsnAlaGlnAlaAlaCysAlaProArg145150155160ArgProProAlaProProHisArgIleProGlyProAlaProGluVal 165170175GluAspLeuAlaArgArgLeuGlyGluValTrpArgGlyAlaValArg180185190 AspTyrGlnGluArgValAlaHisMetGluSerSerLeuGlyGlnAla195200205ArgGluArgLeuSerGlnAlaValArgGlyAlaArgGluCysArgLeu 210215220GluValGlnGlnLeuGlnAlaAspArgAspSerLeuGlnGluArgArg225230235240Glu AlaLeuGluGlnArgLeuGluGlyArgTrpGlnAspArgLeuGln245250255AlaThrAspLysPheGlnLeuAlaValGluAlaLeuGluGlnGluLys 260265270GlnGlyLeuGlnSerGlnIleAlaGlnIleLeuGluGlyGlyGlnGln275280285Leu AlaHisLeuLysMetSerLeuSerLeuGluValAlaThrTyrArg290295300ThrLeuLeuGluAlaGluAsnSerArgLeuGlnThrProGlyArgGly305 310315320SerGlnAlaSerLeuGlyPheLeuAspProLysLeuLysProAsnPhe325330335L euGlyIleProGluAspGlnTyrLeuGlySerValLeuProAlaLeu340345350SerProThrSerPheProSerProLeuProAsnThrLeuGluThrPro 355360365ValThrAlaPheLeuLysThrGlnGluPheLeuGlnAlaArgThrPro370375380ThrLeuAlaSe rThrProIleProProIleSerGluAlaProCysPro385390395400ProAsnAlaGluValArgAlaGlnGluValProLeuSerLeuLeuGln 405410415ThrGlnAlaProGluProLeuTrpLeuLysAlaThrValProSerSer420425430Ser AlaIleLeuProGluLeuGluGluProGlyGlyLysGlnGlnGly435440445HisPheProAspAspLeuThrSerLeuAlaThrAsnLeuAsnProHis 450455460HisProThrLeuGluAlaLysAspGlyGluSerSerGluSerArgVal465470475480SerSer IlePheGlnGluAspGluGlyGlnIleTrpGluLeuValGlu485490495LysGluAlaAspIleGluValLysValGluAsnSerSerAlaGlnLys 500505510ThrGlnGluSerGlyLeuAspThrGluGluThrGlnAspSerGlnGly515520525ProLeuG lnLysGluThrLeuLysAlaLeuGlyGluGluProLeuMet530535540SerLeuLysIleGlnAsnTyrGluThrAlaGlyLysGluAsnCysAsn545 550555560SerSerThrGluGlyHisLeuGlyThrLeuGluGlyProGluLysGlu565570575LysGl nIleProLeuLysSerLeuGluGluLysAsnValGluSerGlu580585590LysThrLeuGluAsnGlyValProValLeuSerGluLeuLeuGlyLys 595600605GluAspThrArgThrGluAspGlnGluLeuMetSerProLysGlyThr610615620LeuLysArgPheSer SerLeuGlyLysGluSerGlnGluValValArg625630635640ProSerLysGluGlyAsnLeuGluSerTrpThrAlaPheLysGluGlu 645650655SerGlnHisProLeuGlyPheProGlyAlaGluAspGlnMetLeuGlu660665670ArgLeu ValGluLysGluAspGlnSerPheProArgSerProGluGlu675680685GluAspGlnGluAlaCysArgProLeuGlnLysGluAsnGlnGluPro690 695700LeuGlyTyrGluGluAlaGluGlyGlnIleLeuGluArgLeuIleGlu705710715720LysGluSerG lnGluSerLeuArgSerProGluGluGluAspGlnGlu725730735AlaGlyArgSerLeuGlnLysGluAsnGlnGluProLeuGlyTyrGlu 740745750GluAlaGluAspGlnMetLeuGluArgLeuIleGluLysGluSerGln755760765GluSerLeuLy sSerProGluGluAsnGlnArgIleGlyLysProLeu770775780GluArgGluAsnGlnLysSerLeuArgTyrLeuGluGluAsnGlnGlu785 790795800ThrPheValProLeuGluSerArgAsnGlnArgProLeuArgSerLeu805810815GluValGlu GluGluGluGlnArgIleValLysProLeuGluLysVal820825830SerGlnAspSerLeuGlySerLeuAlaGluGluAsnValGlnProLeu 835840845ArgTyrLeuGluGluAspAspCysIleAsnLysSerLeuLeuGluAsp850855860LysThrHisLysSerLeu GlySerLeuGluAspArgAsnGlyAspSer865870875880IleIleIleProGlnGluSerGluThrGlnValSerLeuArgProPro 885890895GluGluGluAspGlnArgIleValAsnHisLeuGluLysGluSerGln900905910GluPheSerA rgSerSerGluGluGluGluGlnValMetGluArgSer915920925LeuGluGlyGluAsnHisGluSerLeuSerSerValGluLysGluAsp930 935940GlnMetValGluSerGlnLeuGluLysGluSerGlnAspSerGlyLys945950955960SerLeuGluAspGl uSerGlnGluThrPheGlyProLeuGluLysGlu965970975AsnAlaGluSerLeuArgSerLeuAlaGlyGlnAspGlnGluGluGln 980985990LysLeuGluGlnGluThrGlnGlnThrLeuArgAlaValGlyAsnGlu99510001005GlnMetAlaValSe rProProGluLysValAspProGluLeuProLys101010151020ProLeuGlyAsnAspGlnGluIleAlaArgSerLeuGlyLysGluAsn102510 3010351040GlnGluSerLeuValSerLeuLysGluLysGlyIleGluThrValLys104510501055SerLeuGlu ThrGluIleIleGluProLeuGluThrAlaGluGluAsp106010651070LeuGluArgArgLysSerIleAspThrGlnGluProLeuTrpSerThr 107510801085GluValAlaArgGluThrValGluProProGluAspGluProProGly109010951100SerLeuGlySerValAs pGluAsnArgGluThrLeuThrSerLeuGlu1105111011151120LysGluSerGlnGluLeuSerSerLeuGlyLysTrpAsnValGluThr 112511301135ArgValGluAspSerGlnGlnCysLeuGlnValGluGluGlyLeuGln114011451150GluGlu GlnHisGlnGluSerLeuArgGluValLysGlnGluLeuPro115511601165SerSerGlyAsnGlnGlnArgTrpGluAspValValGluGlyLysAla1170 11751180ValGlyGlnGluAlaProLeuAlaThrThrGlyValGlyThrGluAsp1185119011951200LysAlaGl uLeuHisLeuArgGlyGlnGlyGlyGluGluGluAlaAla120512101215AlaGluGlyGluLeuLeuGlnAspIleValGlyGluAlaTrpSerLeu 122012251230GlySerSerGluProLysGluGlnArgValProAlaGluAlaLeuAsp123512401245AsnLeu GluGlyGlyAlaLeuGluValProValAlaGlnSerMetPro125012551260GluValThrGluArgAspGluAspArgAlaGlnAlaGlyGluGlnAsp1265 127012751280SerIleGluValThrLeuGlyLeuGluAlaAlaArgThrGlyLeuGlu128512901295Le uGluGlnGluValValGlyLeuGluAspProArgHisPheAlaArg130013051310GluGluAlaIleProProSerLeuGlyGluGluSerValLysAlaLys 131513201325IleAlaGlnGlyLeuGluGlyProGlyLysGluProLysGluAlaGly133013351340AlaLeuAsp SerGlyIleLeuGluLeuProLysThrSerSerGluAla1345135013551360LeuGluCysGlnGlyHisGluGluSerGluSerMetGluGlyTrpGlu 136513701375GluGluGluAlaSerLeuGluThrSerAspHisGluGlySerAspAla138013851390 ProGlnProArgProProGluThrGluGluAspGluGlyAlaGlnAla139514001405AlaLeuThrAlaProGlyProLysLeuLeuGluProCysSerProIle 141014151420ProIleLeuThrAspAlaHisGluLeuGlnProGlnAlaGluGlyIle1425143014351440 GlnGluAlaGlyTrpGlnProGluAlaGlySerGluAlaLeuGluArg144514501455ValGluAsnGluProGluPheGlyLeuGlyGluIleProGluGlyLe u146014651470GlnAspTrpGluGluGlyArgGluGluSerGluAlaAspAspLeuGly147514801485 GluThrLeuProAspSerThrProLeuGlyLeuTyrLeuArgSerPro149014951500AlaSerProLysTrpAspLeuAlaGlyGluGlnArgLeuSerProGln15 05151015151520GlyAspAlaGlyLysGluAspTrpGlyProAlaValProAlaAlaGln152515301535GlyLeuSerGlyProProGluGluGluGluGluGlnGlyHisGlySer154015451550AspLeuSerSerGluGluPheGluAspLeuGlyThrGluAlaSe rLeu155515601565LeuProGlyValProLysGluValAlaAspHisValGlyGlnValPro157015751580Pr oValLeuGlnProAlaCysTrpAspGlnGlyGlyGluSerAspGly1585159015951600PheAlaAspGluGluGluSerGlyGluGluGlyGluGluGluAsp Ala160516101615AspGluGluGlyAlaGluSerGlyAlaGlnTrpTrpGlySerGlyAla16201625 1630SerGlyGlyGlyCysLysValGlnAspIleAlaGlnArgGlyAspPro163516401645ValGlnGluSerValGlyValSerGlyLeuTrpAspAspGlyLe uArg165016551660GlyAlaAlaAlaAsnValProAlaLeuGluMetValSerGlnAspSer16651670167516 80AlaGluProSerGlySerGluGluSerGluSerAlaSerLeuGluGly168516901695GluGluGlyGlnValThrAspHisLeuAspAlaProGln GluValThr170017051710SerMetValProGlyValGlyAspAlaPheAspIleGlyGlyGlnSer17151720 1725ProAsnLeuAspSerGluGlnValAsnGlyLysMetGluAsnGlyLeu173017351740GluGlnAlaGluGlyGlnValValLeuAspGlyAspGluAspGlnGl u1745175017551760LeuLeuLeuGlnGlyGlnGluValGlyAlaLeuLysValProLeuVal17651770 1775AlaSerProValHisLeuGlyProSerGlnProLeuLysPheThrLeu178017851790SerGlyValAspGlyAspSerTrpSerSerGlyGlu Asp179518001805(2) INFORMATION FOR SEQ ID NO:3:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 4852 base pairs(B) TYPE: nucleic acid(C) STRANDEDNESS: double(D) TOPOLOGY: linear(ii) MOLECULE TYPE: DNA (genomic)(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:ATGGAGGG CTGCATGGGGGAGGAGTCGTTTCAGATGTGGGAGCTCAATCGGCGCCTGGAG60GCCTACCTGGGCCGGGTCAAGGCGCTGGAGGAGCAGAATGAGCTGCTCAGCGCCGGACTC120GGGGGGCTCCGGCGACAATCCGCGGACACCTCCTGGCGGGCGCATGCCGACGA CGAGCTG180GCGGCCCTGCGTGCGCTCGTTGACCAACGCTGGCGGGAGAAGCACGCGGCCGAGGTGGCG240CGCGACAACCTGGCTGAAGAGCTGGAGGGCGTGGCAGGCCGATGCGAGCAGCTGCGGCTG300GCCCGGGAGCGGACGACGGAGGAGGTAGCC CGCAACCGGCGCGCCGTCGAGGCAGAGAAA360TGCGCCCGGGCCTGGCTGAGTAGCCAGGGGGCAGAGCTGGAGCGCGAGCTAGAGGCTCTA420CGCGTGGCGCACGAGGAGGAGCGCGTCGGTCTGAACGCGCAGGCTGCCTGTGCCCCCCGC480CTGCCCGC GCCGCCCCGGCCTCCCGCGCCGGCCCCGGAGGTAGAGGAGCTGGCAAGGCGA540CTGGGCGAGGCGTGGCGCGGGGCAGTGCGCGGCTACCAGGAGCGCGTGGCACACATGGAG600ACGTCGCTGGACCAGACCCGCGAGCGCCTGGCCCGGGCGGTGCAGGGTGCCCG CGAGGTC660CGCCTGGAGCTACAGCAGCTCCAGGCTGAGCGCGGAGGCCTCCTGGAGCGCAGGGCAGCG720TTGGAACAGAGGTTGGAGGGCCGCTGGCAGGAGCGGCTGCGGGCTACTGAAAAGTTCCAG780CTGGCTGTGGAGGCCCTGGAGCAGGAGAAA CAGGGCCTACAGAGCCAGATCGCTCAGGTC840CTGGAAGGTCGGCAGCAGCTGGCGCACCTCAAGATGTCCCTCAGCCTGGAGGTGGCCACG900TACAGGACCCTCCTGGAGGCTGAGAACTCCCGGCTGCAAACACCTGGCGGTGGCTCCAAG960ACTTCCCT CAGCTTTCAGGACCCCAAGCTGGAGCTGCAATTCCCTAGGACCCCAGAGGGC1020CGGCGTCTTGGATCTTTGCTCCCAGTCCTGAGCCCAACTTCCCTCCCCTCACCCTTGCCT1080GCTACCCTTGAGACACCTGTGCCAGCCTTTCTTAAGAACCAAGAATTCCTCCA GGCCCGT1140ACCCCTACCTTGGCCAGCACCCCCATCCCCCCCACACCTCAGGCACCCTCTCCTGCTGTA1200GATGCAGAGATCAGAGCCCAGGATGCTCCTCTCTCTCTGCTCCAGACACAGGGTGGGAGG1260AAACAGGCTCCAGAGCCCCTGCGGGCTGAA GCCAGGGTGGCCATTCCTGCCAGCGTCCTG1320CCTGGACCAGAGGAGCCTGGGGGCCAGCGGCAAGAGGCCAGTACAGGCCAGTCCCCAGAG1380GACCATGCCTCCTTGGCACCACCCCTCAGCCCTGACCACTCCAGTTTAGAGGCTAAGGAT1440GGAGAATC CGGTGGGTCTAGAGTGTTCAGCATATGCCGAGGGGAAGGTGAAGGGCAAATC1500TGGGGGTTGGTAGAGAAAGAAACAGCCATAGAGGGCAAAGTGGTAAGCAGCTTGCAGCAG1560GAAATATGGGAAGAAGAGGATCTAAACAGGAAGGAAATCCAGGACTCCCAGGT TCCTTTG1620GAAAAAGAAACCCTGAAGTCTCTGGGAGAGGAGATTCAAGAGTCACTGAAGACTCTGGAA1680AACCAGAGCCATGAGACACTAGAAAGGGAGAATCAAGAATGTCCGAGGTCTTTAGAAGAA1740GACTTAGAAACACTAAAAAGTCTAGAAAAG GAAAATAAAAGAGCTATTAAAGGATGTGGA1800GGTAGTGAGACCTCTAGAAAAAGAGGCTGTAGGCAACTTAAGCCTACAGGAAAAGAGGAC1860ACACAGACATTGCAATCCCTGCAAAAGGAGAATCAAGAACTAATGAAATCTCTTGAAGGT1920AATCTAGA GACATTTTTATTTCCAGGAACGGAAAATCAAGAATTAGTAAGTTCTCTGCAA1980GAGAACTTAGAGTCATTGACAGCTCTGGAAAAGGAGAATCAAGAGCCACTGAGATCTCCA2040GAAGTAGGGGATGAGGAGGCACTGAGACCTCTGACAAAGGAGAATCAGGAACC CCTGAGG2100TCTCTTGAAGATGAGAACAAAGAGGCCTTTAGATCTCTAGAAAAAGAGAACCAGGAGCCA2160CTGAAGACTCTAGAAGAAGAGGACCAGAGTATTGTGAGACCTCTAGAAACAGAGAATCAC2220AAATCACTGAGGTCTTTAGAAGAACAGGAC CAAGAGACATTGAGAACTCTTGAAAAAGAG2280ACTCAACAGCGACGGAGGTCTCTAGGGGAACAGGATCAGATGACATTAAGACCCCCAGAA2340AAAGTGGATCTAGAACCACTGAAGTCTCTTGACCAGGAGATAGCTAGACCTCTTGAAAAT2400GAGAATCA AGAGTTCTTAAAGTCACTCAAAGAAGAGAGCGTAGAGGCAGTAAAATCTTTA2460GAAACAGAGATCCTAGAATCACTGAAGTCTGCGGGACAAGAGAACCTGGAAACACTGAAA2520TCTCCAGAAACTCAAGCACCACTGTGGACTCCAGAAGAAATAAATAAATCAGG GGGCAAT2580GAATCCTCTAGAAAAGGAAATTCAAGAACCACTGGAGTCTGTGGAAGTGAACCAAGAGAC2640ATTCAGACTCCTGGAAGAGGAGAATCAGGAATCATTGAGATCTCTGGGAGCATGGAACCT2700GGAGAATTTGAGATCTCCAGAGGAGTAGAC AAGGAAAGTCAAAGGAATCTGGAAGAGGAA2760GAGAACCTGGGAAAGGGAGAGTACCAAGAGTCACTGAGGTCTCTGGAGGAGGAGGGACAG2820GAGCTGCCGCAGTCTGCAGATGTGCAGAGGTGGGAAGATACGGTGGAGAAGGACCAAGAA2880CTGGCTCA GGAAAGCCCTCCTGGGATGGCTGGAGTGGAAAATAAGGATGAGGCAGAGCTG2940AATCTAAGGGAGCAGGATGGCTTCACTGGGAAGGAGGAGGTGGTAGAGCAGGGAGAGCTG3000AATGCCACAGAGGAGGTCTGGTTCCCAGGCGAGGGGCACCCAGAGAACCCTGA GCCCAAA3060GAGCAGAGAGGCCTGGTTGAGGGAGCCAGTGTGAAGGGAGGGGCTGAGGGCCTCCAGGAC3120CCTGAAGGGCAATCACAACAGGTGGGGACCCCAGGCCTCCAGGCTCCCCAGGGGCTGCCA3180GAGGCGATAGAGCCCCTGGTGGAAGATGAT GTGGCCCCAGGGGGTGACCAAGCCTCCCCA3240GAGGTCATGTTGGGGTCAGAGCCTGCCATGGGTGAGTCTGCTGCGGGAGCTGAGCCAGGC3300CTGGGGCAGGGGGTGGGAGGGCTGGGGGACCCAGGCCATCTGACCAGGGAAGAGGTGATG3360GAACCACC CCTGGAAGAGGAGAGTTTGGAGGCAAAGAGGGTTCAGGGCTTGGAAGGGCCT3420AGAAAGGACCTAGAGGAGGCAGGTGGTCTGGGGACAGAGTTCTCCGAGCTGCCTGGGAAG3480AGCAGAGACCCTTGGGAGCCTCCCAGGGAGGGTAGGGAGGAGTCAGAGGCTGA GGCCCCC3540AGGGGAGCAGAGGAGGCGTTCCCTGCTGAGACCCTGGGCCACACTGGAAGTGATGCCCCT3600TCACCTTGGCCTCTGGGGTCAGAGGAAGCTGAGGAGGATGTACCACCAGTGCTGGTCTCC3660CCCAGCCCAACGTACACCCCGATCCTGGAA GATGCCCCTGGGCTCAGCCTCAGGCTGAAG3720GGAGTCAGGAGGCTAGCTGGGGGGTGCAGGGGAGGGCTGAAGCTGGGAAAGTAGAGAGCG3780AGCAGGAGGAGTTGGGTTCTGGGGAGATCCCCGAGGGCCTCCAGGAGGAAGGGGAGGAGA3840GCAGAGAA GAGAGCGAGGAGGATGAGCTCGGGGAGACCCTTCCAGACTCCACTCCCCTGG3900GCTTCTACCTCAGGTCCCCCACCTCCCCCAGGTGGACCCCACTGGAGAGCAGAGGCCACC3960CCCTCAAGGAGACTGGAAAGGAGGGCTGGGATCCTGCTGTCCTGGCTTCCGAG GGCCTTG4020AGGACCCTCAGAAAAGGAGGAGGGGGAGGAGGGAGAAGAGGAGTGTGGCCGTGACTCTGA4080CCTGTCAGAAGAATTTGAGGACCTGGGGACTGAGGCACCTTTTCTTCCTGGGGTCCCTGG4140GGAGGTGGCAGAACCTCTGGGCCAGGTGCC CCAGCTGCTACTGGATCCTGCAGCCTGGGA4200TCGAGATGGGGAGTCTGATGGGTTTGCAGATGAGGAAGAAAGTGGGGAGGAGGGAGAGGA4260GGATCAGGAGGAGGGGAGGGAGCCAGGGGCTGGGCGGTGGGGGCCAGGGTCTTCTGTTGG4320CAGCCTCC AGGCCCTGAGTAGCTCCCAGAGAGGGGAATTCCTGGAGTCTGATTCTGTAAG4380TGTCAGCGTCCCCTGGGATGACAGCTTGAGGGGTGCAGTGGCTGGTGCCCCCAAGACTGC4440CCTGGAAACGGAGTCCCAGGACAGTGCTGAGCCTTCTGGCTCAGAGGAAGAGT CTGACCC4500TGTTTCCTTGGAGAGGGAGGACAAAGTCCCTGGCCCTCTAGAGATCCCCAGTGGGATGGA4560GGATGCAGGCCCAGGGGCAGACATCATTGGTGTTAATGGCCAGGGTCCCAACTTGGAGGG4620GAAGTCACAGCATGTAAATGGGGGAGTAAT GAACGGGCTGGAGCAGTCTGAGGAAAGTGG4680GGCAAGGAATGCGCTAGTCTCTGAGGGAGACCGAGGGAGCCCCTTTCAGGAGGAGGAGGG4740GAGTGCTCTGAAGAGGTCTTCGGCAGGGGCTCCTGTTCACCTGGGCCAGGGTCAGTTCCT4800GAAGTTCA CTCAGAGGGAAGGAGATAGAGAGTCCTGGTCCTCAGGGGAGGAC4852(2) INFORMATION FOR SEQ ID NO:4:(i) SEQUENCE CHARACTERISTICS:(A) LENGTH: 1618 amino acids(B) TYPE: amino acid(D) TOPOLOGY: linear(ii) MOLECULE TYPE: protein(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:MetGluGlyCysMet GlyGluGluSerPheGlnMetTrpGluLeuAsn151015ArgArgLeuGluAlaTyrLeuGlyArgValLysAlaLeuGluGluGln2 02530AsnGluLeuLeuSerAlaGlyLeuGlyGlyLeuArgArgGlnSerAla354045AspThrSerTrpArgAla HisAlaAspAspGluLeuAlaAlaLeuArg505560AlaLeuValAspGlnArgTrpArgGluLysHisAlaAlaGluValAla6570 7580ArgAspAsnLeuAlaGluGluLeuGluGlyValAlaGlyArgCysGlu859095GlnLeuArgLeuAlaArg GluArgThrThrGluGluValAlaArgAsn100105110ArgArgAlaValGluAlaGluLysCysAlaArgAlaTrpLeuSerSer115 120125GlnGlyAlaGluLeuGluArgGluLeuGluAlaLeuArgValAlaHis130135140GluGluGluArgValGlyLeuAsnAla GlnAlaAlaCysAlaProArg145150155160LeuProAlaProProArgProProAlaProAlaProGluValGluGlu165 170175LeuAlaArgArgLeuGlyGluAlaTrpArgGlyAlaValArgGlyTyr180185190GlnGluArgValAlaHis MetGluThrSerLeuAspGlnThrArgGlu195200205ArgLeuAlaArgAlaValGlnGlyAlaArgGluValArgLeuGluLeu2102 15220GlnGlnLeuGlnAlaGluArgGlyGlyLeuLeuGluArgArgAlaAla225230235240LeuGluGlnArgLeuGluGlyA rgTrpGlnGluArgLeuArgAlaThr245250255GluLysPheGlnLeuAlaValGluAlaLeuGluGlnGluLysGlnGly260 265270LeuGlnSerGlnIleAlaGlnValLeuGluGlyArgGlnGlnLeuAla275280285HisLeuLysMetSerLeuSerLe uGluValAlaThrTyrArgThrLeu290295300LeuGluAlaGluAsnSerArgLeuGlnThrProGlyGlyGlySerLys305310 315320ThrSerLeuSerPheGlnAspProLysLeuGluLeuGlnPheProArg325330335ThrProGluGlyArgArgLeu GlySerLeuLeuProValLeuSerPro340345350ThrSerLeuProSerProLeuProAlaThrLeuGluThrProValPro355 360365AlaPheLeuLysAsnGlnGluPheLeuGlnAlaArgThrProThrLeu370375380AlaSerThrProIleProProThrProGln AlaProSerProAlaVal385390395400AspAlaGluIleArgAlaGlnAspAlaProLeuSerLeuLeuGlnThr405 410415GlnGlyGlyArgLysGlnAlaProGluProLeuArgAlaGluAlaArg420425430ValAlaIleProAlaSerValL euProGlyProGluGluProGlyGly435440445GlnArgGlnGluAlaSerThrGlyGlnSerProGluAspHisAlaSer450455 460LeuAlaProProLeuSerProAspHisSerSerLeuGluAlaLysAsp465470475480GlyGluSerGlyGlySerArgValPh eSerIleCysArgGlyGluGly485490495GluGlyGlnIleTrpGlyLeuValGluLysGluThrAlaIleGluGly500 505510LysValValSerSerLeuGlnGlnGluIleTrpGluGluGluAspLeu515520525AsnArgLysGluIleGlnAspSerGln ValProLeuGluLysGluThr530535540LeuLysSerLeuGlyGluGluIleGlnGluSerLeuLysThrLeuGlu545550 555560AsnGlnSerHisGluThrLeuGluArgGluAsnGlnGluCysProArg565570575SerLeuGluGluAspLeuGluThr LeuLysSerLeuGluLysGluAsn580585590LysArgAlaIleLysGlyCysGlyGlySerGluThrSerArgLysArg5956 00605GlyCysArgGlnLeuLysProThrGlyLysGluAspThrGlnThrLeu610615620GlnSerLeuGlnLysGluAsnGlnGluLeuMetL ysSerLeuGluGly625630635640AsnLeuGluThrPheLeuPheProGlyThrGluAsnGlnGluLeuVal645 650655SerSerLeuGlnGluAsnLeuGluSerLeuThrAlaLeuGluLysGlu660665670AsnGlnGluProLeuArgSerProGl uValGlyAspGluGluAlaLeu675680685ArgProLeuThrLysGluAsnGlnGluProLeuArgSerLeuGluAsp690695 700GluAsnLysGluAlaPheArgSerLeuGluLysGluAsnGlnGluPro705710715720LeuLysThrLeuGluGluGluAspGlnSer IleValArgProLeuGlu725730735ThrGluAsnHisLysSerLeuArgSerLeuGluGluGlnAspGlnGlu740 745750ThrLeuArgThrLeuGluLysGluThrGlnGlnArgArgArgSerLeu755760765GlyGluGlnAspGlnMetThrLeuArgPro ProGluLysValAspLeu770775780GluProLeuLysSerLeuAspGlnGluIleAlaArgProLeuGluAsn785790795 800GluAsnGlnGluPheLeuLysSerLeuLysGluGluSerValGluAla805810815ValLysSerLeuGluThrGluIleLeuG luSerLeuLysSerAlaGly820825830GlnGluAsnLeuGluThrLeuLysSerProGluThrGlnAlaProLeu835840 845TrpThrProGluGluIleAsnLysSerGlyGlyAsnGluSerSerArg850855860LysGlyAsnSerArgThrThrGlyValCysGlySerGl uProArgAsp865870875880IleGlnThrProGlyArgGlyGluSerGlyIleIleGluIleSerGly885890 895SerMetGluProGlyGluPheGluIleSerArgGlyValAspLysGlu900905910SerGlnArgAsnLeuGluGluGluGluAsn LeuGlyLysGlyGluTyr915920925GlnGluSerLeuArgSerLeuGluGluGluGlyGlnGluLeuProGln930935 940SerAlaAspValGlnArgTrpGluAspThrValGluLysAspGlnGlu945950955960LeuAlaGlnGluSerProProGlyMetAlaGly ValGluAsnLysAsp965970975GluAlaGluLeuAsnLeuArgGluGlnAspGlyPheThrGlyLysGlu980985 990GluValValGluGlnGlyGluLeuAsnAlaThrGluGluValTrpPhe99510001005ProGlyGluGlyHisProGluAsnProGluPro LysGluGlnArgGly101010151020LeuValGluGlyAlaSerValLysGlyGlyAlaGluGlyLeuGlnAsp102510301035 1040ProGluGlyGlnSerGlnGlnValGlyThrProGlyLeuGlnAlaPro104510501055GlnGlyLeuProGluAlaIleGluProLe uValGluAspAspValAla106010651070ProGlyGlyAspGlnAlaSerProGluValMetLeuGlySerGluPro10751080 1085AlaMetGlyGluSerAlaAlaGlyAlaGluProGlyLeuGlyGlnGly109010951100ValGlyGlyLeuGlyAspProGlyHisLeuThrArg GluGluValMet1105111011151120GluProProLeuGluGluGluSerLeuGluAlaLysArgValGlnGly1125 11301135LeuGluGlyProArgLysAspLeuGluGluAlaGlyGlyLeuGlyThr114011451150GluPheSerGluLeuProGlyLysSe rArgAspProTrpGluProPro115511601165ArgGluGlyArgGluGluSerGluAlaGluAlaProArgGlyAlaGlu11701175 1180GluAlaPheProAlaGluThrLeuGlyHisThrGlySerAspAlaPro1185119011951200SerProTrpProLeuGlySerGluGlu AlaGluGluAspValProPro120512101215ValLeuValSerProSerProThrTyrThrProIleLeuGluAspAla1220 12251230ProGlyLeuGlnProGlnAlaGluGlySerGlnGluAlaSerTrpGly123512401245ValGlnGlyArgAlaGluAlaGlyLy sValGluSerGluGlnGluGlu125012551260LeuGlySerGlyGluIleProGluGlyLeuGlnGluGluGlyGluGlu12651270 12751280SerArgGluGluSerGluGluAspGluLeuGlyGluThrLeuProAsp128512901295SerThrProLeuGlyPheTyr LeuArgSerProThrSerProArgTrp130013051310ThrProLeuGluSerArgGlyHisProLeuLysGluThrGlyLysGlu1315 13201325GlyTrpAspProAlaValLeuAlaSerGluGlyLeuGluGluProSer133013351340GluLysGluGluGlyGluGluGlyGluGl uGluCysGlyArgAspSer1345135013551360AspLeuSerGluGluPheGluAspLeuGlyThrGluAlaProPheLeu1365 13701375ProGlyValProGlyGluValAlaGluProLeuGlyGlnValProGln138013851390LeuLeuLeuAspProAla AlaTrpAspArgAspGlyGluSerAspGly139514001405PheAlaAspGluGluGluSerGlyGluGluGlyGluGluAspGlnGlu1410 14151420GluGlyArgGluProGlyAlaGlyArgTrpGlyProGlySerSerVal1425143014351440GlySerLeuGlnAlaLeuSe rSerSerGlnArgGlyGluPheLeuGlu144514501455SerAspSerValSerValSerValProTrpAspAspSerLeuArgGly1460 14651470AlaValAlaGlyAlaProLysThrAlaLeuGluThrGluSerGlnAsp147514801485SerAlaGluProSerGly SerGluGluGluSerAspProValSerLeu149014951500GluArgGluAspLysValProGlyProLeuGluIleProSerGlyMet15051510 15151520GluAspAlaGlyProGlyAlaAspIleIleGlyValAsnGlyGlnGly152515301535ProAsnLeuGluGl yLysSerGlnHisValAsnGlyGlyValMetAsn154015451550GlyLeuGluGlnSerGluGluSerGlyAlaArgAsnAlaLeuValSer1555 15601565GluGlyAspArgGlySerProPheGlnGluGluGluGlySerAlaLeu157015751580LysArgSerSerAlaGlyAla ProValHisLeuGlyGlnGlyGlnPhe1585159015951600LeuLysPheThrGlnArgGluGlyAspArgGluSerTrpSerSerGly 160516101615GluAsp
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
WO1989003872A1 *Oct 28, 1988May 5, 1989Amrad Corp LtdGeneration of neural precursor cell lines
Non-Patent Citations
Reference
1Beug, H., et al., "Hormone-Dependent Terminal Differentiation in Vitro of Chicken Erythroleukemia Cells Transformed by ts Mutants of Avian Erythroblastosis Virus", Cell 28:907-919 (1982).
2 *Beug, H., et al., Hormone Dependent Terminal Differentiation in Vitro of Chicken Erythroleukemia Cells Transformed by ts Mutants of Avian Erythroblastosis Virus , Cell 28:907 919 (1982).
3Chou, J. Y., "Establishment of Rat Fetal Liver Lines and Characterization of Their Metabolic and Hormonal Properties: Use of Temperature-Sensitive SV40 Virus", Methods in Enzym. 109:385-395 (1985).
4 *Chou, J. Y., Establishment of Rat Fetal Liver Lines and Characterization of Their Metabolic and Hormonal Properties: Use of Temperature Sensitive SV40 Virus , Methods in Enzym. 109:385 395 (1985).
5Frederiksen, K., et al., "Immortalization of Precursor Cells from the Mammalian CNS", Neuron 1:439-448 (1988).
6Frederiksen, K., et al., "Proliferation & Differentiation of Rat Neuroepithelial Precursor Cells in vivo", J. of Neuroscience Annl. 8(4):1155-1151 (1988).
7 *Frederiksen, K., et al., Immortalization of Precursor Cells from the Mammalian CNS , Neuron 1:439 448 (1988).
8 *Frederiksen, K., et al., Proliferation & Differentiation of Rat Neuroepithelial Precursor Cells in vivo , J. of Neuroscience Annl. 8(4):1155 1151 (1988).
9Hockfield, S., et al., "Identification of Major Cell Classes in the Developing Mammalian Nervous System", J. of Neuroscience 5(12):3310-3328 (1985).
10 *Hockfield, S., et al., Identification of Major Cell Classes in the Developing Mammalian Nervous System , J. of Neuroscience 5(12):3310 3328 (1985).
11 *International Search Report; Patent Cooperation Treaty Search Report PCTUS92101375.
12Jat, P. S., et al., "Cell Lines Established by a Temperature-Sensitive Simian Virus 40 Large-T-Antigen Gene are Growth Restricted at the Nonpermissive Temperature", Mol. & Cell. Biol. 9(4):1672-1681 (1989).
13Jat, P. S., et al., "Recombinant Retroviruses Encoding Simian Virus 40 Large T Antigen & Polyomavirus Large & Middle T Antigens", Mol. & Cell. Biol. 6(4):1204-1217 (1986).
14 *Jat, P. S., et al., Cell Lines Established by a Temperature Sensitive Simian Virus 40 Large T Antigen Gene are Growth Restricted at the Nonpermissive Temperature , Mol. & Cell. Biol. 9(4):1672 1681 (1989).
15 *Jat, P. S., et al., Recombinant Retroviruses Encoding Simian Virus 40 Large T Antigen & Polyomavirus Large & Middle T Antigens , Mol. & Cell. Biol. 6(4):1204 1217 (1986).
16Jat., P. S., et al., "Large T. Antigens of Simian Virus 40 and Polymavirus Efficiently Establish Primary Fibroblasts", J. of Virol. 59(3):746-750 (1986).
17 *Jat., P. S., et al., Large T. Antigens of Simian Virus 40 and Polymavirus Efficiently Establish Primary Fibroblasts , J. of Virol. 59(3):746 750 (1986).
18Lendahl, U., et al., "CNS Stem cells express a new class of Intermediate filament protein", Cell 60:585-595 (1990).
19Lendahl, U., et al., "CNS Stem Cells Express a New Class of Intermediate Filament Protein", Cell, 60:585-595 (Feb. 23, 1990).
20 *Lendahl, U., et al., CNS Stem cells express a new class of Intermediate filament protein , Cell 60:585 595 (1990).
21 *Lendahl, U., et al., CNS Stem Cells Express a New Class of Intermediate Filament Protein , Cell, 60:585 595 (Feb. 23, 1990).
22McKay R. D., et al., "Molecular cloning of nestin: a novel intermediate filament restricted to CNS stem cells", J. Cell. Biochem. Suppl., p. 223 (1990).
23 *McKay R. D., et al., Molecular cloning of nestin: a novel intermediate filament restricted to CNS stem cells J. Cell. Biochem. Suppl., p. 223 (1990).
24McKay, R. D., "A cerebeller stem cell model for meduiloblastona" (Abstr. 10.30.08) Cancer Research & Clinical Oncology, 116 (1990).
25 *McKay, R. D., A cerebeller stem cell model for meduiloblastona (Abstr. 10.30.08) Cancer Research & Clinical Oncology, 116 (1990).
26Petit, C. A., et al., "Immortalization of Rodent Embryo Fibroblasts by SV40 is Maintained by the A Gene", Virology 127:74-82 (1983).
27 *Petit, C. A., et al., Immortalization of Rodent Embryo Fibroblasts by SV40 is Maintained by the A Gene , Virology 127:74 82 (1983).
28Redies, C., et al., "Differentiation and Heterogeneity in T-Antigen Immortalized Precursor Cell Lines From Mouse Cerebellum", J. of Neurosci. Res., 30:601-615 (1991).
29 *Redies, C., et al., Differentiation and Heterogeneity in T Antigen Immortalized Precursor Cell Lines From Mouse Cerebellum , J. of Neurosci. Res., 30:601 615 (1991).
30Reh, T. A., et al., "Age of Differentiation Determines Rat Retinal Germinal Cell Phenotype: Induction of Differentiation by Dissociation" J. of Neuroscience 9(12):4179-4189 (1989).
31 *Reh, T. A., et al., Age of Differentiation Determines Rat Retinal Germinal Cell Phenotype: Induction of Differentiation by Dissociation J. of Neuroscience 9(12):4179 4189 (1989).
32Temple, S., et al., "Clonal Analysis of Oligodendrocyte Development in Culture: Evidence for a Developmental Clock that Counts Cell Divisions" Cell 44:773-779 (1986).
33 *Temple, S., et al., Clonal Analysis of Oligodendrocyte Development in Culture: Evidence for a Developmental Clock that Counts Cell Divisions Cell 44:773 779 (1986).
34Tohyama, T., et al., "Nestin Expression in Embryonic Human Neuroepithelium and in Human Neuroepithelial Tumor Cells", Laboratory Investigation 66(3):303-313 (1992).
35 *Tohyama, T., et al., Nestin Expression in Embryonic Human Neuroepithelium and in Human Neuroepithelial Tumor Cells , Laboratory Investigation 66(3):303 313 (1992).
36Valtz, N. L. M., et al., "An Embryonic Origin for Medulloblastoma" The New Biologist, 3(4):364-371 (1991).
37 *Valtz, N. L. M., et al., An Embryonic Origin for Medulloblastoma The New Biologist, 3(4):364 371 (1991).
38Watanabe, T., et al., "Rod Photoreceptor Development In Vitro: Intrinsic Properties of Proliferating Neuroepithelial Cells Change as Development Proceeds in the Rat Retina", Neuron 4:461-467 (1990).
39 *Watanabe, T., et al., Rod Photoreceptor Development In Vitro: Intrinsic Properties of Proliferating Neuroepithelial Cells Change as Development Proceeds in the Rat Retina , Neuron 4:461 467 (1990).
40Zimmerman et al., "Molecular Cloning of Nestin: A Novel Intermediate Filament Restriction to CNS Stem Cells" (Abst. B121); Cancer Research and Clinical Oncology 116 (1990).
41 *Zimmerman et al., Molecular Cloning of Nestin: A Novel Intermediate Filament Restriction to CNS Stem Cells (Abst. B121); Cancer Research and Clinical Oncology 116 (1990).
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US6245564Jan 23, 1997Jun 12, 2001Cornell Research Foundation, Inc.Method for separating cells
US6280739Jun 27, 1997Aug 28, 2001Genetics Institute, Inc.Method of inhibiting angiogenesis using secreted proteins
US6303370 *Mar 24, 1998Oct 16, 2001Mayo Foundation For Medical Education And ResearchTissue-specific regulatory elements
US6322976 *Mar 17, 1999Nov 27, 2001Medical Research CouncilCompositions and methods of disease diagnosis and therapy
US6692957Apr 17, 2001Feb 17, 2004Cornell Research Foundation, Inc.Method for separating cells
US6787355Sep 25, 2000Sep 7, 2004Mcgill UniversityMultipotent neural stem cells from peripheral tissues and uses thereof
US6878543 *Oct 24, 2000Apr 12, 2005Nsgene SaCultures of GFAP+ nestin+ cells that differentiate to neurons
US6969608Aug 22, 1997Nov 29, 2005Mcgill UniversityPharmaceuticals containing multipotential precursor cells from tissues containing sensory receptors
US7150989Aug 9, 2002Dec 19, 2006Cornell Research Foundation, Inc.Telomerase immortalized neural progenitor cells
US7303912Feb 22, 2005Dec 4, 2007Nsgene A/SCultures of GFAP nestin cells that differentiate to neurons
US7488809May 21, 2003Feb 10, 2009Insem-TransfertChimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest
US7651853Oct 31, 2007Jan 26, 2010Nsgene A/SCultures of GFAP+ nestin+ cells that differentiate to neurons
US8263402Mar 31, 1999Sep 11, 2012Cornell Research Foundation, Inc.Method for isolating and purifying oligodendrocytes and oligodendrocyte progenitor cells
US8367071Feb 13, 2003Feb 5, 2013Inserm-TransfertVerotoxin B subunit for immunization
US8388943Jul 6, 2006Mar 5, 2013Mcgill UniversityMultipotent stem cells from peripheral tissues and uses thereof
US8501467Dec 23, 2009Aug 6, 2013Stemcells California, Inc.Cultures of GFAP+ nestin+ cells that differentiate to neurons
US8524652Dec 31, 2008Sep 3, 2013InsermChimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest
US8617882Jun 6, 2008Dec 31, 2013The Hospital For Sick ChildrenSkin-derived precursor cells and uses thereof
US8748177Mar 30, 2011Jun 10, 2014The Hospital For Sick ChildrenCompositions for proliferation of cells and related methods
US20020016002 *Jul 26, 2001Feb 7, 2002Jean TomaMultipotent neural stem cells from peripheral tissues and uses thereof
US20020123143 *Nov 9, 2001Sep 5, 2002Jean TomaMultipotent stem cells from peripheral tissues and uses thereof
US20020178460 *May 16, 2002Nov 28, 2002Cold Spring Harbor LaboratoryTransgenic mice expressing fluorescent protein
US20030082812 *Aug 9, 2002May 1, 2003Goldman Steven A.Telomerase immortalized human neural stem cells and phenotypically-restricted progenitor cells
US20040005301 *Feb 10, 2003Jan 8, 2004Goldman Steven A.Identification and high-yield isolation of human pancreatic islet progenitor and stem cells
US20040047883 *May 21, 2003Mar 11, 2004Bruno GoudChimeric polypeptide comprising the fragment B of shiga toxin and peptides of therapeutic interest
US20040137507 *Feb 17, 2004Jul 15, 2004Goldman Steven A.Method for separating cells
US20050191745 *Feb 22, 2005Sep 1, 2005Lars WahlbergCultures of GFAP nestin cells that differentiate to neurons
US20070110730 *Jul 6, 2006May 17, 2007Jean TomaMultipotent stem cells from peripheral tissues and uses thereof
US20080138895 *Oct 31, 2007Jun 12, 2008Lars WahlbergCultures of gfap+ nestin+ cells that differentiate to neurons
US20100322913 *Dec 31, 2008Dec 23, 2010InsermChimeric polypeptide comprising the fragment b of shiga toxin and peptides of therapeutic interest
US20110003358 *Jan 6, 2011Nsgene A/SCultures of gfap+ nestin+ cells that differentiate to neurons
CN1328378C *Nov 30, 2000Jul 25, 2007中国科学院上海生命科学研究院Mouse nidogen gene starter and its tissue specificity enhancer
EP2072060A1Dec 18, 2007Jun 24, 2009Institut CurieMethods and compositions for the preparation and use of toxin conjugates.
WO2000019883A2 *Oct 7, 1999Apr 13, 2000Timothy J AitmanCompositions and methods of disease diagnosis and therapy
WO2001053461A1 *Jan 24, 2001Jul 26, 2001Mahnaz AkhavanMultipotent neural stem cells from peripheral tissues and uses thereof
Classifications
U.S. Classification536/23.5, 435/91.2, 536/24.31, 435/6.16
International ClassificationC07K16/18, C07K14/47, C12N5/0797
Cooperative ClassificationC12N5/0623, C07K14/47, C07K16/18, C12N2510/04
European ClassificationC07K14/47, C12N5/06B8P, C07K16/18
Legal Events
DateCodeEventDescription
Jun 1, 1992ASAssignment
Owner name: MASSACHUSETTS INSTITUTE OF TECHNOLOGY, A CORP. OF
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:MCKAY, RONALD D.;REEL/FRAME:006148/0552
Effective date: 19920522
Feb 20, 1998SULPSurcharge for late payment
Feb 20, 1998FPAYFee payment
Year of fee payment: 4
Feb 6, 2002FPAYFee payment
Year of fee payment: 8
Jan 27, 2006FPAYFee payment
Year of fee payment: 12